Pharmaceutical preparations containing anti-OX40 monoclonal antibodies

Abstract

Disclosed are pharmaceutical formulations that include monoclonal OX40 antibodies, buffers, stabilizers, and surfactants, and that can maintain stability under various scenarios, such as manufacturing, packaging, subpackaging, shipping, administration, and / or storage. Also disclosed are uses of the pharmaceutical formulations in the preparation of medicaments for treating OX40-related diseases, particularly inflammatory and / or autoimmune diseases, and methods for preparing the pharmaceutical formulations.

Description

[Technical Field]

[0001] FIELD OF THE DISCLOSURE

[0001] The present disclosure relates to pharmaceutical formulations, and in particular to stable pharmaceutical formulations comprising monoclonal anti-OX40 antibodies or antigen-binding fragments thereof. [Background technology]

[0002]

[0002] Antibodies against the human OX40 receptor (OX40) have been developed to treat various diseases, such as autoimmune diseases, inflammatory diseases, or other disorders, such as cancer. However, these antibodies are known to be insufficiently stable and often undergo various chemical and physical degradations. In particular, the higher-order structure of antibodies is very fragile and prone to structural changes such as denaturation, aggregation, and precipitation.

[0003] Denaturation refers to changes in the physical, chemical, and / or biological properties of antibodies, which have been associated with increased immunogenicity. Protein aggregation occurs when a protein molecule self-associates with one or more additional protein molecules, often resulting in decreased physiological activity that impacts drug efficacy and an increased likelihood of immunological or antigenic reactions in patients. Precipitation occurs, for example, when changes in pH or hydrophobicity alter the interactions between the protein molecule and the aqueous environment, or when the intramolecular interactions of functional groups on a protein molecule are disrupted through salt or metal binding. Such degradation or instability products, as well as aggregation or precipitation, can have a significant adverse effect on the biological activity and safety of biological substances. For example, aggregation, protein aggregates, or mixed aggregates with inactive excipients included in pharmaceutical formulations of therapeutic proteins can lead to immunogenic reactions. See Schellekens, H. Nat. Rev. Drug Discov. 1:457-62 (2002); and Hesmeling et al., Pharm. Res. 22:1997-2006 (2005). Summary of the Invention [Problem to be solved by the invention]

[0004]

[0004] Therefore, there is a need for new pharmaceutical formulations of antibodies, such as monoclonal anti-OX40 antibodies, which have increased stability and reduced toxicity of the pharmaceutical formulation. [Means for solving the problem]

[0005]

[0005] The present disclosure provides stable pharmaceutical formulations comprising monoclonal anti-OX40 antibodies that remain homogeneous and stable over extended periods of time.

[0006] In one aspect, the disclosure provides a pharmaceutical formulation comprising a monoclonal anti-OX40 antibody or antigen-binding fragment thereof, a buffer, a stabilizer, and a surfactant.

[0006]

[0007] In certain embodiments, the monoclonal anti-OX40 antibody comprises a heavy chain and a light chain, wherein the heavy chain is HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1; HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 2; HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 3 A heavy chain variable region V comprising H Including, Light chains are LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 4; LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 5; LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6 a light chain variable region V comprising L Including, The heavy chain further comprises an Fc region variant, the Fc region variant being human IgG1 N297A.

[0007]

[0008] In certain embodiments, the heavy chain variable region V H comprises an amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9, and SEQ ID NO:10.

[0009] In certain embodiments, the light chain variable region V Lcomprises an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:11, and SEQ ID NO:12.

[0008]

[0010] In certain embodiments, the concentration of the monoclonal anti-OX40 antibody in the pharmaceutical formulation is about 0.5 to 200 mg / ml, preferably about 40 to 60 mg / ml.

[0011] In certain embodiments, the pharmaceutical formulation has a pH of about 5.0 to 8.0.

[0009]

[0012] In certain embodiments, the buffer is selected from the group consisting of acetate buffer, histidine buffer, citrate buffer, glutamate buffer, arginine buffer, citrate & arginine buffer, glutamate & histidine buffer, aspartate & histidine buffer, and the concentration of the buffer in the pharmaceutical formulation is about 1-100 mmol / L.

[0010]

[0013] In certain embodiments, the stabilizer is selected from the group consisting of sucrose, sorbitol, trehalose, xylitol, and mannose, and the concentration of the stabilizer in the pharmaceutical formulation is about 0.5% to 50% w / v.

[0011]

[0014] In certain embodiments, the surfactant is selected from the group consisting of polysorbate 80 and polysorbate 20, and the concentration of the surfactant in the pharmaceutical formulation is about 0.001-0.1% w / v.

[0012]

[0015] In certain embodiments, the concentration of the monoclonal anti-OX40 antibody in the pharmaceutical formulation is about 40-60 mg / ml, the concentration of the buffer in the pharmaceutical formulation is about 10-30 mmol / L, the concentration of the stabilizer in the pharmaceutical formulation is about 4-12% w / v, the concentration of the surfactant in the pharmaceutical formulation is about 0.01-0.05% w / v, and / or the pharmaceutical formulation has a pH of about 5.0-6.0.

[0013]

[0016] In certain embodiments, the concentration of the monoclonal anti-OX40 antibody in the pharmaceutical formulation is about 50 mg / ml, the concentration of the buffer in the pharmaceutical formulation is about 20 mmol / L, the concentration of the stabilizer in the pharmaceutical formulation is about 4.5-8.8% w / v, the concentration of the surfactant in the pharmaceutical formulation is about 0.02-0.04% w / v, and / or the pharmaceutical formulation has a pH of about 5.0-5.5.

[0014]

[0017] In certain embodiments, the concentration of the stabilizer in the pharmaceutical formulation is about 8% w / v, the concentration of the surfactant in the pharmaceutical formulation is about 0.02% w / v, and / or the pharmaceutical formulation has a pH of about 5.0.

[0015]

[0018] In certain embodiments, the buffer is a glutamic acid and histidine buffer, an aspartic acid and histidine buffer, or a combination thereof, the stabilizer is sucrose, sorbitol, trehalose, or a combination thereof, and / or the surfactant is polysorbate 80.

[0016]

[0019] In certain embodiments, the pharmaceutical formulations provided herein comprise: a monoclonal anti-OX40 antibody or antigen-binding fragment thereof at a concentration of about 40 to 60 mg / ml; Glutamic acid & histidine buffer or aspartic acid & histidine buffer at a concentration of approximately 10 to 30 mmol / L, sucrose at a concentration of approximately 4–12% w / v, and Polysorbate 80 at a concentration of approximately 0.01-0.05% w / v Including, The pharmaceutical formulation has a pH of about 5.0 to 5.5.

[0017]

[0020] In certain embodiments, the pharmaceutical formulations provided herein comprise: a monoclonal anti-OX40 antibody or antigen-binding fragment thereof at a concentration of about 50 mg / ml; Glutamic acid & histidine buffer or aspartic acid & histidine buffer at a concentration of approximately 20 mmol / L, sucrose at a concentration of approximately 8% w / v, and Polysorbate 80 at a concentration of approximately 0.02% w / v Including, The pharmaceutical formulation has a pH of about 5.0.

[0018]

[0021] In certain embodiments, the pharmaceutical formulation is suitable for subcutaneous or intravenous administration.

[0022] In another aspect, the present disclosure also provides the use of a pharmaceutical formulation provided herein in the manufacture of a medicament for the treatment or prevention of an OX40-associated disease.

[0019]

[0023] In certain embodiments, the OX40-associated disease is an inflammatory and / or autoimmune disease, such as graft-versus-host disease.

[0024] In another aspect, the present disclosure also provides a method of treating an OX40-related disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation provided herein.

[0020]

[0025] In certain embodiments, administration is by subcutaneous or intravenous injection.

[0026] In another aspect, the present disclosure also provides a method of preparing the pharmaceutical formulations provided herein, the method comprising combining a buffer, a stabilizer, a surfactant, and a pharmaceutically effective amount of a monoclonal anti-OX40 antibody or antigen-binding fragment thereof.

[0021]

[0027] In another aspect, the present disclosure also provides a kit comprising, in one or more containers, a pharmaceutical formulation provided herein.

[0028] In certain embodiments, the kits provided herein further comprise instructions for using the kit. [Brief explanation of the drawings]

[0022] [Figure 1]

[0029] Figure 1 shows the protein concentration results from the solubility profiling study. [Figure 2]

[0030] Figure 2 shows the DSC overlay for the pH / buffer screen. [Figure 3]

[0031] FIG. 3 shows the trend of the main peak by SEC-HPLC. [Figure 4]

[0032] FIG. 4 shows the HMW trends by SEC-HPLC. [Figure 5]

[0033] FIG. 5 shows the trend of LMW by SEC-HPLC. [Figure 6]

[0034] FIG. 6 shows the trend of the main peaks by iCIEF. [Figure 7]

[0035] FIG. 7 shows the trend of acidic peaks by iCIEF. [Figure 8]

[0036] FIG. 8 shows the trend of basic peaks by iCIEF. [Figure 9]

[0037] Figure 9 shows the purity trend by Caliper-NR. [Figure 10]

[0038] Figure 10 shows the purity trend by Caliper-R. [Figure 11]

[0039] Figure 11 shows the DSC overlay. [Figure 12]

[0040] FIG. 12 shows the trend of the main peak by SEC-HPLC. [Figure 13]

[0041] FIG. 13 shows the HMW trends by SEC-HPLC. [Figure 14]

[0042] FIG. 14 shows the trends of LMW by SEC-HPLC. [Figure 15]

[0043] FIG. 15 shows the trend of the main peak by iCIEF. [Figure 16]

[0044] FIG. 16 shows the trend of acidic peaks by iCIEF. [Figure 17]

[0045] FIG. 17 shows the trend of basic peaks by iCIEF. [Figure 18]

[0046] FIG. 18 shows the purity trend by Caliper-SDS-NR. [Figure 19]

[0047] FIG. 19 shows the purity trends by Caliper-SDS-R. DETAILED DESCRIPTION OF THE INVENTION

[0023]

[0048] The following description of the present disclosure is intended only to illustrate various embodiments of the present disclosure. The specific examples described should not be construed as limiting the scope of the present disclosure. It is understood that those skilled in the art may make various equivalents, variations, and modifications without departing from the spirit and scope of the present disclosure, and that equivalents are also encompassed herein. All references cited herein, including publications, patents, and patent applications, are incorporated herein by reference in their entirety.

[0024]

[0049] definition

[0050] As used herein, the terms "a," "an," or "the" refer to both the singular and the plural, unless the context clearly dictates otherwise.

[0025]

[0051] Reference herein to "about" a value or parameter includes (and describes) embodiments directed to that value or parameter per se. For example, a statement referring to "about X" includes the statement "X." Numerical ranges include the numbers defining the range. Generally speaking, the term "about" refers to the indicated value of the variable and all values ​​of the variable that are within experimental error for the indicated value (e.g., within a 95% confidence interval for the mean) or within 10 percent of the indicated value, whichever is greater. When the term "about" is used in the context of a period of time (years, months, weeks, days, etc.), the term "about" means that period of time plus or minus one amount of the next subperiod of time (e.g., about 1 year means 11-13 months; about 6 months means 6 months plus or minus 1 week; about 1 week means 6-8 days, etc.), or within 10 percent of the indicated value, whichever is greater.

[0026]

[0052] Unless otherwise defined, scientific and technical terms used in connection with this disclosure shall have the meanings commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include the plural and plural terms shall include the singular. Generally, the nomenclature utilized in connection with the techniques of cell and tissue culture, molecular biology, and protein and oligo- or polynucleotide chemistry, the laboratory procedures, and the techniques of analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art.

[0027]

[0053] As used herein, the term "pharmaceutical formulation" refers to a combination of one or more active pharmaceutical ingredients (APIs) and at least one other ingredient, e.g., for further processing (e.g., lyophilization, reconstitution, titration, dilution), storage, sale, and / or administration by a particular route at a particular dose, to treat a particular disease.

[0028]

[0054] The term "active pharmaceutical ingredient" or "API," as used herein, refers to a macromolecule, such as a polypeptide, nucleic acid, lipid, or carbohydrate, or a component thereof, which can be used as a therapeutic agent, such as a therapeutic antibody (e.g., a monoclonal anti-OX40 antibody) or an antigen-binding fragment thereof.

[0029]

[0055] When describing a range of values, it should be understood that the described feature may have individual values ​​within the range. For example, "a pH of about 5.0 to 8.0" refers to, but is not limited to, pH 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, etc., as well as any values ​​in between. The term "pH of about 5.0 to 8.0" should not be construed as the pH of the pharmaceutical formulation varying by 3 pH units from pH 5.0 to pH 8.0 during manufacturing, packaging, subpackaging, shipping, administration and / or storage; rather, the term "pH of about 5.0 to 8.0" refers to a selected value in the range of about 5.0 to 8.0 for the pH of the solution, and the pH is buffered at about the selected pH value during manufacturing, packaging, subpackaging, shipping, administration and / or storage.

[0030]

[0056] As used herein, "treating" or "treatment of" a condition includes preventing or alleviating the condition, slowing the onset or rate of development of the condition, reducing the risk of developing the condition, preventing or slowing the development of symptoms associated with the condition, reducing or terminating symptoms associated with the condition, causing complete or partial regression of the condition, curing the condition, or some combination thereof.

[0031]

[0057] The term "subject" includes humans and non-human animals. Non-human animals include all vertebrates, e.g., mammals and non-mammals such as non-human primates, mice, rats, cats, rabbits, sheep, dogs, cows, chickens, amphibians, and reptiles. Unless otherwise indicated, the terms "patient" and "subject" are used interchangeably herein.

[0032]

[0058] formulation

[0059] The present disclosure provides novel pharmaceutical formulations that maintain increased stability of APIs under a variety of different manufacturing, packaging, subpackaging, shipping, administration, and storage conditions. The pharmaceutical formulations of the present disclosure also exhibit reduced toxicity and increased therapeutic efficacy. APIs used in conjunction with the pharmaceutical formulations provided herein may include, in particular, therapeutic antibodies, such as monoclonal anti-OX40 antibodies or antigen-binding fragments thereof.

[0033]

[0060] In one aspect, the present disclosure provides a pharmaceutical formulation comprising a monoclonal anti-OX40 antibody or antigen-binding fragment thereof, a buffer, a stabilizer, and a surfactant. In some embodiments, the pharmaceutical formulation has a pH of about 5.0 to 8.0 (e.g., about 5.0 to 6.0, about 5.0 to 5.5, or about 5.0).

[0034]

[0061] In a further aspect, the present disclosure provides a method for preparing a monoclonal anti-OX40 antibody or antigen-binding fragment thereof at a concentration of about 0.5 to 200 mg / ml (e.g., about 1 to 180 mg / ml, about 10 to 160 mg / ml, about 15 to 140 mg / ml, about 20 to 120 mg / ml, about 25 to 100 mg / ml, about 30 to 80 mg / ml, about 40 to 60 mg / ml, or about 50 mg / ml) in a buffer (e.g., a glutamic acid and histidine buffer, or aspartic acid & histidine buffer) at a concentration of about 1-100 mmol / L (e.g., about 10-90 mmol / L, about 10-80 mmol / L, about 10-70 mmol / L, about 10-60 mmol / L, about 10-50 mmol / L, about 10-40 mmol / L, about 10-30 mmol / L, or about 20 mmol / L) and a stabilizing agent (e.g., sucrose, sorbitol, or trehalose) at about 0.5%-50% w / v (e.g., about 10-150 mmol / L). For example, about 1% to about 40% (w / v), about 2% to about 30% (w / v), about 3% to about 20% (w / v), about 3.2% to about 18% (w / v), about 3.4% to about 16% (w / v), about 3.6% to about 14% (w / v), about 4% to about 12% (w / v), about 6% to about 10% (w / v), or about 8% (w / v)), and a surfactant (e.g., polysorbate 80 (PS80) or polysorbate 20 (PS20)) at a concentration of about 0.0 The present invention provides a pharmaceutical formulation comprising the compound at a concentration of about 0.01 to 0.1% (w / v) (e.g., about 0.002% to about 0.08% (w / v), about 0.004% to about 0.06% (w / v), about 0.006% to about 0.05% (w / v), about 0.008% to about 0.05% (w / v), about 0.01% to about 0.05% (w / v), or about 0.02% (w / v)) at a pH of about 5.0 to 8.0 (e.g., about 5.0 to 6.0, about 5.0 to 5.5, or about 5.0).

[0035]

[0062] In a further aspect, the present disclosure provides a method for preparing a monoclonal anti-OX40 antibody or antigen-binding fragment thereof at a concentration of about 0.5 to 200 mg / ml (e.g., about 1 to 180 mg / ml, about 10 to 160 mg / ml, about 15 to 140 mg / ml, about 20 to 120 mg / ml, about 25 to 100 mg / ml, about 30 to 80 mg / ml, about 40 to 60 mg / ml, or about 50 mg / ml) in a buffer (e.g., a glutamic acid and histidine buffer, or Also provided is a pharmaceutical formulation comprising a soluble ...

[0036]

[0063] In another aspect, the present disclosure provides a method for preparing a monoclonal anti-OX40 antibody or antigen-binding fragment thereof at a concentration of about 0.5 to 200 mg / ml (e.g., about 1 to 180 mg / ml, about 10 to 160 mg / ml, about 15 to 140 mg / ml, about 20 to 120 mg / ml, about 25 to 100 mg / ml, about 30 to 80 mg / ml, about 40 to 60 mg / ml, or about 50 mg / ml), a buffer (e.g., glutamic acid and histidine buffer, or aspartic acid and histidine buffer) at a concentration of about 20 mmol / L, and a stabilizer (e.g., sucrose, PEG-10 ... Also provided are pharmaceutical formulations comprising a surfactant (e.g., polysorbate 80) at a concentration of about 0.01% to about 0.05% (w / v) (e.g., about 0.01% to about 0.04% (w / v), about 0.015% to about 0.035% (w / v), about 0.02% to about 0.03% (w / v), about 0.025% (w / v), or about 0.02% (w / v)), at a pH of about 5.0 to 6.0 (e.g., about 5.0 to 5.5 or about 5.0).

[0037]

[0064] The pharmaceutical formulations provided herein exhibit enhanced stability, with improved resistance to changes such as temperature, humidity, time, and physical movement (e.g., agitation). As used herein, the term "stability" with respect to a pharmaceutical formulation refers to the optimal retention (not necessarily 100%) of the structure, function, and / or biological activity of an API (e.g., a monoclonal anti-OX40 antibody or antigen-binding fragment thereof) within the pharmaceutical formulation. As used herein, the term "retention of stability" with respect to a pharmaceutical formulation refers to the relative value (expressed as a percentage) of the stability of a pharmaceutical formulation after storage under certain conditions compared to the stability of the pharmaceutical formulation before such storage.

[0038]

[0065] The stability of a pharmaceutical formulation can include the physical stability, chemical stability, and / or physicochemical stability of the API.

[0066] Physical stability can be reflected by the percentage of protein monomer, which can be determined by measuring, for example, by size exclusion chromatography (SEC), the percentage of monomer before and after storage under certain conditions.

[0039]

[0067] Chemical stability can be reflected by the level of chemical modifications, such as deamidation, pyroglutamic acid formation, and / or lysine truncation, which can be determined by measuring charge heterogeneity before and after storage under certain conditions, for example, by imaging capillary isoelectric focusing (iCIEF) using cation exchange chromatography (CEX) and / or anion exchange chromatography (AEX) analysis. iCIEF results can include a main peak, an acidic peak, and a basic peak, along with the pI of the main peak. The acidic peak represents acidic species and is defined as an antibody variant that elutes earlier than the main peak during cation exchange chromatography (CEX) or later than the main peak during anion exchange chromatography (AEX) analysis. Acidic species can be formed through modifications including sialic acid, deamidation, non-classical disulfide bonds, trisulfide bonds, high mannose, glycation, maleuric acid modification, cysteinylation, reduced disulfide bonds, non-reducing species, and / or fragments. The basic peak represents basic species and is defined as material eluting later than the main peak during CEX and earlier than the main peak during AEX analysis. Basic species can be formed through modifications including isomerization of C-terminal Lys, N-terminal Glu, and Asp, succinimide, Met oxidation, amidation, incomplete disulfide bonds, incomplete removal of leader sequences, Ser to Arg mutation, glycosylation, fragmentation, and / or aggregation. The main peak refers to the main species and represents the target antibody molecule eluting as the main peak on the chromatogram. The main species does not necessarily correspond to unmodified or undegraded antibody. In fact, the main peak typically consists of antibody species with three types of typical post-translational modifications: (1) cyclization of N-terminal glutamine (Gln) to pyroGlu; (2) removal of C-terminal lysine (Lys) from the heavy chain; and (3) glycosylation of the conserved asparagine (Asn) residue in the CH2 domain with neutral oligosaccharides. Chemical stabilization can also be reflected in the purity (eg, truncation or fragmentation level) of the API before and after storage under certain conditions, for example, by Caliper-SDS and SEC.

[0040]

[0068] The physicochemical stability of an API can be reflected by the level of low molecular weight percentage (LMW%) and / or the level of high molecular weight percentage (HMW%). As used herein, the term "low molecular weight percentage" is used interchangeably with the term "LMW%" and refers to the percentage of low molecular weight (LMW) impurities (e.g., Fab, Fc, and single chains), which can arise through several pathways, such as hydrolysis, free radical-induced fragmentation, and enzymatic cleavage, and exhibit physicochemical instability during manufacturing, storage, transportation, and administration. As used herein, the term "high molecular weight percentage" is used interchangeably with the term "HMW%" and refers to the percentage of high molecular weight (HMW) impurities (e.g., dimers, trimers, and multimers), which are formed through various mechanisms, such as molecular interactions and chemical cross-linking, and exhibit colloidal and conformational instability during manufacturing, storage, transportation, and administration. LMW% and HMW% can be determined, for example, by SEC, by measurement before and after storage under certain conditions.

[0041]

[0069] The stability of the pharmaceutical formulation may also include thermal stability, which may be reflected by the temperature at which the protein begins to unravel (i.e., Tmonset) and / or the temperature at which the first / second protein domain is half-unraveled (i.e., Tm1 / Tm2), as measured by differential scanning calorimetry (DSC).

[0042]

[0070] The stability of a pharmaceutical formulation can also include the thermodynamic stability of the API, which can be reflected by Tagg and / or kD when measured by dynamic light scattering (DLS). DLS provides information on the hydrodynamic size and size distribution of particles (e.g., anti-OX40 antibodies or antigen-binding fragments thereof) in solution, which is typically examined as a function of time and temperature. The temperature at which protein molecules (e.g., anti-OX40 antibodies or antigen-binding fragments thereof) begin to show a tendency to oligomerize or aggregate is termed the aggregation temperature (Tagg). Tagg depends on the buffer composition. The higher the Tagg, the more stable the protein (e.g., anti-OX40 antibodies or antigen-binding fragments thereof) is, and the protein is believed to have a longer shelf life. The information provided by DLS can also be analyzed to determine the translational diffusion coefficient, which is a function of concentration; analysis of the translational diffusion coefficient versus concentration yields the diffusion interaction parameter kD. A positive kD indicates a repulsive interaction, while a negative kD indicates an attractive intermolecular interaction. Positive kD values ​​represent repulsive intermolecular interactions, while negative kD values ​​represent attractive intermolecular interactions, so a more positive kD value means a lesser tendency to aggregate.

[0043]

[0071] In some embodiments, antibody protein concentration, protein purity, protein activity, formulation pH, formulation osmolality, formulation appearance, insoluble particles in the formulation, etc. may serve as indicators of pharmaceutical formulation stability. Various analytical techniques for measuring protein stability are available in the art and are reviewed in Peptide and Protein Drug Delivery, pp. 247-301, edited by Vincent Lee, Marcel Dekker Inc. New York, New York Press (1991) and Jones, A. Adv. Drug Delivery Rev. 10:29-90 (1993). In some embodiments, the stability of a pharmaceutical formulation can be measured by methods known in the art for a selected period of time under selected conditions.

[0044]

[0072] In some embodiments, the percentage of monomer remaining after storage (4 weeks at 40° C.) or repeated freeze-thaw (5 cycles of freeze-thaw) or agitation (3 days at 25° C. with agitation) of the API of the pharmaceutical formulations provided herein can be between about 80% and about 100%, between about 85% and about 99%, between about 90% and about 99%, or between about 95% and about 99%, as measured by SEC-HPLC. Thus, the API in the pharmaceutical formulations of the present disclosure can retain at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or even 100% of its physical stability relative to the starting physical stability of the API after storage (40° C. for 4 weeks) or repeated freeze-thaw (5 freeze-thaw cycles) or agitation (25° C. with agitation for 3 days), as measured by SEC-HPLC.

[0045]

[0073] In some embodiments, the API in the pharmaceutical formulations provided herein, after storage (2 or 4 weeks at 40°C) or repeated freeze-thaw (3 cycles of freeze-thaw) or agitation (3 days of agitation at 25°C), has LMW impurities (e.g., Fab, Fc, and single chain) of about 0.1% to about 3.4%, about 0.15% to about 3.35%, about 0.2% to about 3.3%, about 0.3% to about 3.2%, about 0.4% to about 3.1%, or about 0.6% to about 2%, as measured by SEC-HPLC. Thus, the API in the pharmaceutical formulation of the present disclosure can retain at least 96.6%, at least 97%, at least 98%, at least 99.0%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or even at least 99.9% of its physicochemical stability at the starting point after storage (at 40° C. for 2 or 4 weeks) or repeated freeze-thawing (three cycles of freeze-thawing) or agitation (at 25° C. with agitation for 3 days), as measured by SEC-HPLC. In particular, the API in the pharmaceutical formulations provided herein has only about 0.1% LMW impurities (e.g., Fab, Fc, and single chain) after three repeated freeze-thaw cycles or three days of agitation at 25°C, as measured by SEC-HPLC; therefore, the API in the pharmaceutical formulations of the present disclosure can retain about 99.9% of its starting physicochemical stability after three repeated freeze-thaw cycles or three days of agitation at 25°C, as measured by SEC-HPLC.

[0046]

[0074] In some embodiments, the purity of the API of the pharmaceutical formulations provided herein after storage (4 weeks at 40°C) or repeated freeze-thaw (5 cycles of freeze-thaw) or agitation (3 days at 25°C with agitation) can be about 90% to about 99%, about 91% to about 99%, about 92% to about 99%, about 93% to about 99%, about 94% to about 99%, or about 95% to about 99%, as measured by non-reducing Caliper-SDS. Thus, the API in the pharmaceutical formulations of the present disclosure can retain at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99.0%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9%, or even 100% of its chemical stability relative to the starting chemical stability of the API after storage (40° C. for 4 weeks) or repeated freeze-thaw (5 cycles of freeze-thaw) or agitation (25° C. with agitation for 3 days), as measured by non-reducing Caliper-SDS.

[0047]

[0075] In some embodiments, the purity of the API of the pharmaceutical formulations provided herein after storage (4 weeks at 40°C) or repeated freeze-thaw (5 cycles of freeze-thaw) or agitation (3 days at 25°C with agitation) can be about 90% to about 100%, about 91% to about 100%, about 92% to about 100%, about 93% to about 100%, about 94% to about 100%, or about 95% to about 100%, as measured by reduced Caliper-SDS. Thus, the API in the pharmaceutical formulations of the present disclosure can retain at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99.0%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9%, or even 100% of its chemical stability relative to the starting chemical stability of the API after storage (40° C. for 4 weeks) or repeated freeze-thaw (5 cycles of freeze-thaw) or agitation (25° C. with agitation for 3 days), as measured by reduced Caliper-SDS.

[0048]

[0076] In some embodiments, the T of the pharmaceutical formulations provided herein is greater than or equal to about 50°C, greater than or equal to about 50.5°C, greater than or equal to about 51°C, greater than or equal to about 51.5°C, greater than or equal to about 52°C, greater than or equal to about 52.5°C, or greater than or equal to about 53°C, as measured by DSC.

[0049]

[0077] In certain embodiments, the Tm1 of the pharmaceutical formulations provided herein is about 60°C or higher, about 60.1°C or higher, about 60.2°C or higher, about 60.3°C or higher, about 60.4°C or higher, about 60.5°C or higher, about 60.6°C or higher, about 60.7°C or higher, about 60.8°C or higher, about 60.9°C or higher, about 61°C or higher, about 61.2°C or higher, about 61.4°C or higher, about 61.6°C or higher, about 61.8°C or higher, about 62°C or higher, about 62.2°C or higher, about 62.4°C or higher, about 62.6°C or higher, about 62.8°C or higher, about 63°C or higher, or about 63.2°C or higher, as measured by DSC.

[0050]

[0078] In certain embodiments, the Tm2 of the pharmaceutical formulations provided herein is about 75°C or higher, about 76°C or higher, about 76.1°C or higher, about 76.2°C or higher, about 76.3°C or higher, about 76.4°C or higher, about 76.5°C or higher, about 76.6°C or higher, about 76.7°C or higher, about 76.8°C or higher, about 76.9°C or higher, about 77°C or higher, about 77.2°C or higher, about 77.4°C or higher, about 77.6°C or higher, about 77.8°C or higher, about 78°C or higher, about 78.1°C or higher, about 78.2°C or higher, or about 78.3°C or higher, as measured by DSC.

[0051]

[0079] In certain embodiments, the kD of the pharmaceutical formulations provided herein is about 10 or greater, about 11 or greater, about 12 or greater, about 12.5 or greater, about 13 or greater, about 13.5 or greater, about 14 or greater, about 15 or greater, about 16 or greater, about 17 or greater, about 18 or greater, or about 19 or greater, as measured by DLS at 20°C to 40°C.

[0052]

[0080] In certain embodiments, the Tag of the pharmaceutical formulations provided herein is about 59°C or greater, about 59.2°C or greater, about 59.4°C or greater, about 59.6°C or greater, about 59.8°C or greater, about 60°C or greater, about 60.2°C or greater, about 60.4°C or greater, about 60.6°C or greater, about 60.8°C or greater, about 61°C or greater, about 61.2°C or greater, or about 61.4°C or greater, as measured by DLS for a formulation comprising API at a concentration between 2 mg / mL and 10 mg / mL.

[0053]

[0081] In some embodiments, the stability of the pharmaceutical formulations provided herein can be measured by the appearance of the formulation after storage (e.g., at 40°C for 1, 2, or 4 weeks), repeated freeze-thawing (e.g., 3 or 5 cycles of freeze-thawing from -70°C to room temperature), or agitation (e.g., at 300 rpm at 25°C for 1 or 3 days). In certain embodiments, no visible particles were observed in the pharmaceutical formulations of the present disclosure.

[0054]

[0082] In some embodiments, the stability of the pharmaceutical formulations provided herein can be measured by the pH of the formulation after storage (e.g., at 40°C for 1, 2, or 4 weeks), repeated freeze-thawing (e.g., 3 or 5 cycles of freeze-thawing from -70°C to room temperature), or agitation (e.g., at 300 rpm at 25°C for 1 or 3 days). In certain embodiments, little change in pH was observed in the pharmaceutical formulations of the present disclosure after storage compared to the formulation at the starting point.

[0055]

[0083] In some embodiments, the stability of the pharmaceutical formulations provided herein can be measured by the API concentration of the formulation after storage (e.g., 2 or 4 weeks at 40°C), repeated freeze-thawing (e.g., 3 or 5 cycles of freeze-thawing from -70°C to room temperature), or agitation (e.g., 300 rpm at 25°C for 1 or 3 days). In certain embodiments, the change in API concentration is 2% or less, 1.9% or less, 1.8% or less, 1.7% or less, 1.6% or less, 1.5% or less, 1.4% or less, 1.3% or less, 1.2% or less, 1.1% or less, 1.0% or less, 0.9% or less, 0.8% or less, 0.7% or less, 0.6% or less, 0.5% or less, 0.4% or less, 0.3% or less, 0.2% or less, or 0.1% or less compared to the API concentration in the starting formulation, as determined by UV280 readings using a spectrophotometer. In certain embodiments, no change in API concentration was observed in the pharmaceutical formulations of the present disclosure.

[0056]

[0084] In some embodiments, the stability of the pharmaceutical formulations provided herein can be measured by the number of submicroscopic particles in the formulation after storage (e.g., 4 weeks at 40°C), repeated freeze-thawing (e.g., 5 cycles of freeze-thawing from -70°C to room temperature), or agitation (e.g., 300 rpm, 25°C, 3 days), e.g., as shown in Table 18 of Example 4. In particular, the number of submicroscopic particles in the formulation after agitation (e.g., at 300 rpm, 25°C, for 3 days) is less than 1500 / mL, 1400 / mL, 1300 / mL, 1200 / mL, 1100 / mL, 1000 / mL, 900 / mL, 800 / mL, 700 / mL, 600 / mL, 500 / mL, 400 / mL, 300 / mL, 200 / mL, 100 / mL, 90 / mL, 80 / mL, 70 / mL, 60 / mL, 50 / mL, 40 / mL, 30 / mL, 20 / mL, 10 / mL, or even less than 2 / mL. Submicroscopic particles may induce anti-drug antibodies in patients, which may adversely affect therapeutic efficacy and / or induce an aberrant immune response.

[0057]

[0085] In some embodiments, the stability of the pharmaceutical formulations provided herein can be measured by the activity (e.g., binding ability) of the API. The activity of the API can be measured, for example, using in vitro, in vivo, and / or in situ assays that indicate the functionality of the API. Retention of API stability in the pharmaceutical formulations of the present disclosure can include, for example, retention of about 50% to about 100% or more of the API's activity after 4 weeks of storage at 40°C, depending on the variability of the assay. For example, the pharmaceutical formulations provided herein can retain about 80% to about 99%, about 85% to about 99%, about 86% to about 99%, about 88% to about 99%, about 90% to about 99%, about 92% to about 99%, about 94% to about 99%, about 96% to about 99%, or about 98% to about 99% of the API's activity at the starting point after storage or repeated freeze-thawing or agitation of the API in the pharmaceutical compositions provided herein, as measured by a binding assay.

[0058]

[0086] In some embodiments, the retention of activity of an API of the pharmaceutical formulation of the present disclosure can be at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, or at least 99%. In some other embodiments, the retention of activity of an API of the pharmaceutical formulation of the present disclosure can be greater than 100%, e.g., 102%, 104%, 106%, 108%, 110%, or 112% or more, relative to the starting activity of the API after storage or repeated freeze-thawing or agitation of the API of the pharmaceutical composition.

[0059]

[0087] The term "starting point," as used herein, refers to the time when an API is first prepared in a pharmaceutical formulation or first tested for quality (e.g., physical and / or chemical stability), which may be represented as TO.

[0060]

[0088] In some embodiments, the pharmaceutical formulations of the present disclosure can remain stable for extended periods of time, with the stability and / or functional activity of the API remaining relatively constant over time. The pharmaceutical formulations of the present disclosure can be subjected to long-term stability testing, e.g., the pharmaceutical formulation can be stored at 2-8°C for one year, with samples taken for measurements at 1 month, 3 months, 6 months, and 12 months. In certain embodiments, the pharmaceutical formulations of the present disclosure can remain stable and functional for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, or at least 12 months.

[0061]

[0089] The pharmaceutical formulations of the present disclosure may be approved for pharmaceutical use by an international or national authority competent by law to grant approval for pharmaceutical use, such as the China National Medical Products Administration (NMPA), the United States Food and Drug Administration (FDA), the European Medicines Evaluation Agency (EMEA), the Japanese Ministry of Health, Labour and Welfare (MHLW), the Australian Therapeutic Goods Administration (TGA), the Taiwan Food and Drug Administration (TFDA), or any successor agency(ies) thereof with this authority, with the NMPA or any successor agency(ies) thereof with this authority being particularly preferred.

[0062]

[0090] One advantage of the present disclosure is the provision of pharmaceutical formulations that are stabilized against stresses that may occur during manufacturing, packaging, subpackaging, shipping, administration, and / or storage, and have reduced toxicity and increased therapeutic efficacy. The stabilized pharmaceutical formulations provided herein may increase ease of administration, reduce the frequency of administration, and reduce the amount of pain experienced by patients upon injection. For example, administration by intravenous or subcutaneous parenteral routes is safer and more effective if the pharmaceutical formulation maintains physical, chemical, physicochemical, and / or thermal stability during manufacturing, packaging, subpackaging, shipping, storage, and administration.

[0063]

[0091] The stability of the API in a pharmaceutical composition against stresses occurring during manufacturing, packaging, subpackaging, transportation, administration, and storage is primarily provided by various excipients in the pharmaceutical composition. As used herein, the term "excipient" refers to therapeutically inactive substances such as buffers, stabilizers, surfactants, isotonicity agents, cryoprotectants, bulking agents, diluents, lyoprotectants, vehicles, metal ion sources, antioxidants, preservatives, and / or chelating agents, which are well known in the art and whose descriptions can be found, for example, in Wang W. Int. J. Pharm. 203:1-60 (2000) and Wang W. Int. J. Pharm. 185:129-88 (1999). The composition of excipients in the pharmaceutical formulations provided herein minimizes the degree of proteolysis / optimizes protein stability, thereby maintaining the safety and efficacy of the API. A detailed description of the excipients used in the pharmaceutical formulations of the present disclosure follows.

[0064]

[0092] buffer

[0093] Maintaining a desired pH of a pharmaceutical formulation is believed to positively affect the stability, efficacy, and shelf life of the pharmaceutical formulation. To maintain pH, one or more buffering reagents or agents can be included in the pharmaceutical formulation. The term "buffer" refers to a buffer that resists changes in pH through the action of its acid-base conjugate components, which are known to be safe for use in pharmaceutical formulations and maintain or control the pH of the formulation within a desired range. Acceptable buffers capable of controlling pH in the weakly acidic to weakly alkaline pH range (e.g., pH 5.0-8.0) include, but are not limited to, one or any combination of phosphate buffer, acetate buffer, citrate buffer, arginine buffer, 2-amino-2-hydroxymethyl-1,3-propanediol (TRIS) buffer, histidine buffer, glutamate buffer, aspartate buffer, glutamate and histidine buffer, aspartate and histidine buffer, citrate and arginine buffer, and the like.

[0065]

[0094] The pharmaceutical formulations of the present disclosure may include a buffer that allows the pharmaceutical formulation to have a pH of 5.0 to 8.0, such as a pH of 5.0 to 5.5, 5.5 to 6.5, or 6.5 to 8.0. In some embodiments, a suitable buffer allows the pharmaceutical formulations of the present disclosure to have a pH of 5.0 to 6.0. In some embodiments, a suitable buffer allows the pharmaceutical formulations of the present disclosure to have a pH of 5.0 to 5.5. In particular, the pH of the pharmaceutical formulations of the present disclosure can be any pH value in the pH ranges listed above, such as 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.0. In a preferred embodiment, a suitable buffering agent enables the pharmaceutical formulations of the present disclosure to have a pH of about 5.0.

[0066]

[0095] Examples of buffers that can control the pH of pharmaceutical formulations within a desired range include acetate buffers, arginine buffers, glutamate buffers, aspartate buffers, histidine buffers, citrate buffers, phosphate buffers, and other organic or inorganic acid buffers. These buffers can be used alone or in combination of two or more of these buffers.

[0067]

[0096] "Glutamic acid buffer," used interchangeably with "glutamate buffer," refers to a buffer containing glutamic acid, optionally in equilibrium with its respective conjugate base. The glutamic acid form of glutamic acid buffer can contain glutamic acid, glutamate ions, and / or glutamate, including glutamate salts such as sodium, potassium, ammonium, calcium, or magnesium salts of glutamate. The term includes both the L- and D-forms of glutamic acid. The buffering capacity of a glutamic acid buffer is highly related to the pKa value of glutamic acid. It is well recognized that the buffer zone of an amino acid is the pH range near its pKa value. Glutamic acid has pKa values ​​of 2.2 and 9.7, as well as a side chain pKa of 4.3. A detailed description of the pKa values ​​of amino acids can be found, for example, in "Amino Acids, the Henderson-Hasselbalch Equation, and Isoelectric Points." (September 28, 2021, retrieved October 12, 2021 from https: / / chem.libretexts.org / @go / page / 36468). Therefore, glutamate buffers are considered to have buffer capacities of approximately these values.

[0068]

[0097] A "histidine buffer" refers to a buffer containing histidine ions. Histidine buffers can include one or more of histidine, histidine hydrochloride, histidine acetate, histidine phosphate, histidine sulfate, and the like. Histidine has pKa values ​​of 1.8 and 9.2, and a side chain pKa of 6.0; therefore, histidine buffers are considered to have buffer capacities of approximately these values. In some embodiments, the histidine buffer is a histidine-histidine hydrochloride buffer. In some embodiments, the pH of the histidine buffer can be any pH value in the range of 5.5 to 6.5, such as 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, or 6.5.

[0069]

[0098] The term "aspartate buffer," used interchangeably with "aspartate buffer," refers to a buffer containing aspartic acid, optionally in equilibrium with its conjugate base. This buffer can be made from an aspartate salt, such as sodium aspartate, potassium aspartate, ammonium aspartate, calcium aspartate, or magnesium aspartate. Aspartic acid has pKa values ​​of 2.1 and 9.8, as well as a side chain pKa of 3.9. A detailed description of the pKa values ​​of aspartic acid can be found, for example, in "Amino Acids, the Henderson-Hasselbalch Equation, and Isoelectric Points." (September 28, 2021), https: / / chem.libretexts.org / @go / page / 36468, retrieved October 12, 2021). Therefore, it is believed that aspartate buffers have buffer capacities of approximately these values.

[0070]

[0099] A "citrate buffer" is a buffer containing citrate ions. The citrate buffer may include one or more of citric acid, monosodium citrate, disodium citrate, trisodium citrate, monopotassium citrate, dipotassium citrate, tripotassium citrate, sodium chloride, potassium chloride, and the like. The pH of the citrate buffer can be any pH value between 3.0 and 6.2.

[0071] [000100] As used herein, the term "arginine buffer" refers to a buffer containing arginine in equilibrium with its conjugate acid, such as HCl. Arginine has a pKa of 2.1, 9.0, and a side chain pKa of 12.5; a detailed description of arginine's pKa values ​​can be found, for example, in "Amino Acids, the Henderson-Hasselbalch Equation, and Isoelectric Points." (September 28, 2021), https: / / chem.libretexts.org / @go / page / 36468, retrieved October 12, 2021). Therefore, arginine buffers are considered to have buffer capacities of approximately these values.

[0072] [000101] The term "acetate buffer," used interchangeably with "acetic acid buffer," refers to a buffer containing acetic acid in equilibrium with its respective conjugate base. The buffer can be made from acetate salts such as sodium acetate, potassium acetate, ammonium acetate, calcium acetate, or magnesium acetate. The pH of citrate buffers can be any pH value between 3.6 and 5.8.

[0073] [000102] The term "glutamic acid & histidine buffer," which can be used interchangeably with the terms "glutamic acid and histidine buffer," "glutamic acid / histidine buffer," or "glutamine / histidine buffer," refers to a buffer system comprising a glutamic acid buffer and a histidine buffer, optionally with an acid or base to adjust the final pH, such as HCl or NaOH. The glutamic acid portion of the glutamic acid & histidine buffer can include glutamic acid, glutamate ions, and / or glutamate, including glutamate salts, such as sodium, potassium, ammonium, calcium, or magnesium salts of glutamate. The term includes both the L- and D-forms of glutamic acid. In some embodiments, the glutamic acid & histidine buffer consists of glutamic acid and histidine, optionally with an acid or base to adjust the final pH, such as HCl or NaOH. In some embodiments, the pH of the glutamic acid & histidine buffer can be any pH value in the range of 5.0 to 8.0.

[0074] [000103] The term "aspartic acid & histidine buffer," which can be used interchangeably with the terms "aspartic acid and histidine buffer" or "aspartic acid / histidine buffer," refers to a buffer system comprising an aspartic acid buffer and a histidine buffer, optionally with an acid or base to adjust the final pH, such as HCl or NaOH. The aspartic acid form of the aspartic acid & histidine buffer can include aspartic acid, aspartate ion, and / or aspartate, including aspartate salts, such as sodium, potassium, ammonium, calcium, or magnesium salts of aspartate. The term includes both the L- and D-forms of aspartic acid. In some embodiments, the aspartic acid & histidine buffer consists of aspartic acid and histidine, optionally with an acid or base to adjust the final pH, such as HCl or NaOH. In some embodiments, the pH of the aspartic acid and histidine buffer can be any pH value in the range of 5.0 to 8.0.

[0075] [000104] The term "citric acid & arginine buffer," which may be used interchangeably with the terms "citric acid and arginine buffer" or "citric acid / arginine buffer," refers to a buffer system comprising a citrate buffer and an arginine buffer, optionally with an acid or base to adjust the final pH, such as HCl or NaOH. In some embodiments, the citrate & arginine buffer consists of citric acid and arginine, optionally with an acid or base to adjust the final pH, such as HCl or NaOH. In some embodiments, the pH of the citrate & arginine buffer can be any pH value between 4.0 and 8.0.

[0076] [000105] In some embodiments, the pharmaceutical formulations of the present disclosure comprise a glutamic acid and histidine buffer or an aspartic acid and histidine buffer at a pH of about 5.0 to 8.0. In some embodiments, the pharmaceutical formulations of the present disclosure comprise a glutamic acid and histidine buffer consisting of glutamic acid and histidine at a pH of about 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.0. In some embodiments, the pharmaceutical formulations of the present disclosure comprise a glutamic acid and histidine buffer consisting of glutamic acid and histidine at a pH of about 5.0 to 6.0. In some embodiments, the pharmaceutical formulations of the present disclosure comprise a glutamic acid and histidine buffer consisting of glutamic acid and histidine at a pH of about 5.0 to 5.5. In some embodiments, the pharmaceutical formulations of the present disclosure comprise a glutamic acid and histidine buffer consisting of glutamic acid and histidine at a pH of about 5.0.

[0077] [000106] In some embodiments, the pharmaceutical formulations of the present disclosure comprise an aspartic acid and histidine buffer consisting of aspartic acid and histidine at a pH of about 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.0. In some embodiments, the pharmaceutical formulations of the present disclosure comprise an aspartic acid and histidine buffer consisting of aspartic acid and histidine at a pH of about 5.0-6.0. In some embodiments, the pharmaceutical formulations of the present disclosure comprise an aspartic acid and histidine buffer consisting of aspartic acid and histidine at a pH of about 5.0 to 5.5. In some embodiments, the pharmaceutical formulations of the present disclosure comprise an aspartic acid and histidine buffer consisting of aspartic acid and histidine at a pH of about 5.0.

[0078] [000107] As used herein, the term "concentration of a buffering agent" refers to the concentration of buffer ions in a buffering agent. In some embodiments, a suitable concentration of a buffering agent used in a pharmaceutical formulation of the present disclosure may be 1 to 100 mmol / L. In some embodiments, the concentration of a buffering agent is any concentration value within the above range. For example, the concentration of a buffering agent is about 10 to 90 mmol / L, about 10 to 80 mmol / L, about 10 to 70 mmol / L, about 10 to 60 mmol / L, about 10 to 50 mmol / L, about 10 to 40 mmol / L, about 10 to 30 mmol / L, or about 20 mmol / L. In some embodiments, the concentration of a buffering agent is any concentration value within the above range. For example, the concentration of the buffering agent is about 11-29 mmol / L, about 12-28 mmol / L, about 13-27 mmol / L, about 14-26 mmol / L, about 15-25 mmol / L, about 16-24 mmol / L, about 17-23 mmol / L, about 18-22 mmol / L, or about 19-21 mmol / L, depending on the particular buffering agent and the desired stability of the pharmaceutical formulation.

[0079] [000108] In some embodiments, the pharmaceutical formulations of the present disclosure may be buffered at a concentration of at least 2 mmol / L, at least 3 mmol / L, at least 4 mmol / L, at least 5 mmol / L, at least 6 mmol / L, at least 7 mmol / L, at least 8 mmol / L, at least 9 mmol / L, at least 11 mmol / L, at least 12 mmol / L, at least 13 mmol / L, at least 14 mmol / L, at least 15 mmol / L, at least 16 mmol / L, at least 17mmol / L, at least 18mmol / L, at least 19mmol / L, at least 22mmol / L, at least 22mmol / L, at least 23mmol / L, at least 24mmol / L, at least 25mmol / L, at least 26mmol / L, at least 27mmol / L, at least 28mmol / L, at least 29mmol / L, at least 31mmol / L, at least 32mmol / L, at least 33mmol / L, at least 34mmol / L, at least 35mmol / L, at least 36mmol / L, at least at least 37mmol / L, at least 38mmol / L, at least 39mmol / L, at least 41mmol / L, at least 42mmol / L, at least 43mmol / L, at least 44mmol / L, at least 45mmol / L, at least 46mmol / L, at least 47mmol / L, at least 48mmol / L, at least 49mmol / L, at least 51mmol / L, at least 52mmol / L, at least 53mmol / L, at least 54mmol / L, at least 55mmol / L, at least 56mmol / L, at least at least 57mmol / L, at least 58mmol / L, at least 59mmol / L, at least 61mmol / L, at least 62mmol / L, at least 63mmol / L, at least 64mmol / L, at least 65mmol / L, at least 66mmol / L, at least 67mmol / L, at least 68mmol / L, at least 69mmol / L, at least 71mmol / L, at least 72mmol / L, at least 73mmol / L, at least 74mmol / L, at least 75mmol / L, at least 76mmol / L,At least 77 mmol / L, at least 78 mmol / L, at least 79 mmol / L, at least 81 mmol / L, at least 82 mmol / L, at least 83 mmol / L, at least 84 mmol / L, at least 85 mmol / L, at least 86 mmol / L, at least 87 mmol / L, at least 88 mmol / L, at least 89 mmol / L, at least 91 mmol / L, at least 92 mmol / L, at least 93 mmol / L, at least 94 mmol / L, at least 95 mmol / L, at least 96 mmol / L, at least 97 mmol / L, at least 98 mmol / L, or at least 99 mmol / L.

[0080] [000109] In some embodiments, the pharmaceutical formulations of the present disclosure may comprise a buffering agent at up to 2 mmol / L, up to 3 mmol / L, up to 4 mmol / L, up to 5 mmol / L, up to 6 mmol / L, up to 7 mmol / L, up to 8 mmol / L, up to 9 mmol / L, up to 11 mmol / L, up to 12 mmol / L, up to 13 mmol / L, up to 14 mmol / L, up to 15 mmol / L, up to 16 mmol / L, up to 17 mmol / L, up to 18 mmol / L, up to 19 mmol / L, or up to 20 mmol / L, depending on the particular buffering agent and the desired stability of the pharmaceutical formulation. l / L, max 22mmol / L, max 22mmol / L, max 23mmol / L, max 24mmol / L, max 25mmol / L, max 26mmol / L, max 27mmol / L, max 28mmol / L, max 29mmol / L, max 31mmol / L, max 32mmol / L, max 33mmol / L, max 34mmol / L, max 35mmol / L, max 36mmol / L, max 37mmol / L, max 38mmol / L, max 39mmol / L, max 41mmol / L, max 42mmol / L, max 43 mmol / L, max 44mmol / L, max 45mmol / L, max 46mmol / L, max 47mmol / L, max 48mmol / L, max 49mmol / L, max 51mmol / L, max 52mmol / L, max 53mmol / L, max 54mmol / L, max 55mmol / L, max 56mmol / L, max 57mmol / L, max 58mmol / L, max 59mmol / L, max 61mmol / L, max 62mmol / L, max 63mmol / L, max 64mmol / L, max 65mmol / L, max 66mmol / L, max 67mmol / L, max 68mmol / L, max 69mmol / L, max 71mmol / L, max 72mmol / L, max 73mmol / L, max 74mmol / L, max 75mmol / L, max 76mmol / L, max 77mmol / L, max 78mmol / L, max 79mmol / L, max 81mmol / L, max 82mmol / L, max 83mmol / L, max 84mmol / L, max 85mmol / L, max 86mmol / L, max 87mmol / L, max 88mmol / LContains concentrations of up to 89mmol / L, up to 91mmol / L, up to 92mmol / L, up to 93mmol / L, up to 94mmol / L, up to 95mmol / L, up to 96mmol / L, up to 97mmol / L, up to 98mmol / L, or up to 99mmol / L.

[0081] [000110] Other concentrations of buffering agent are also contemplated by this disclosure, provided that the buffering agent has sufficient buffering capacity to maintain the selected pH of the formulation in a particular scenario, such as manufacturing, packaging, subpackaging, shipping, administration, and / or storage.

[0082] [000111] In some embodiments, the pharmaceutical formulation of the present disclosure includes a glutamic acid and histidine buffer. In some embodiments, the pharmaceutical formulation of the present disclosure includes the glutamic acid and histidine buffer at a concentration of 1 to 100 mmol / L. In some embodiments, the pharmaceutical formulation of the present disclosure includes the glutamic acid and histidine buffer at any concentration within the above range. For example, the pharmaceutical formulation of the present disclosure includes the glutamic acid and histidine buffer at a concentration of about 10 to 90 mmol / L, about 10 to 80 mmol / L, about 10 to 70 mmol / L, about 10 to 60 mmol / L, about 10 to 50 mmol / L, about 10 to 40 mmol / L, about 10 to 30 mmol / L, or about 20 mmol / L. In some embodiments, the pharmaceutical formulations of the present disclosure contain a glutamic acid and histidine buffer at a concentration of about 11-29 mmol / L, about 12-28 mmol / L, about 13-27 mmol / L, about 14-26 mmol / L, about 15-25 mmol / L, about 16-24 mmol / L, about 17-23 mmol / L, about 18-22 mmol / L, or about 19-21 mmol / L. In some embodiments, the pharmaceutical formulations of the present disclosure contain a glutamic acid and histidine buffer at any concentration within the above ranges.

[0083] [000112] In some embodiments, the pharmaceutical formulation of the present disclosure comprises a glutamic acid & histidine buffer at a concentration of at least 2 mmol / L, at least 3 mmol / L, at least 4 mmol / L, at least 5 mmol / L, at least 6 mmol / L, at least 7 mmol / L, at least 8 mmol / L, at least 9 mmol / L, at least 11 mmol / L, at least 12 mmol / L, at least 13 mmol / L, at least 14 mmol / L, at least 15 mmol / L, at least 16 mmol / L, at least 17 mmol / L, at least 18mmol / L, at least 19mmol / L, at least 22mmol / L, at least 22mmol / L, at least 23mmol / L, at least 24mmol / L, at least 25mmol / L, at least 26mmol / L, at least 27mmol / L, at least 28mmol / L, at least 29mmol / L, at least 31mmol / L, at least 32mmol / L, at least 33mmol / L, at least 34mmol / L, at least 35mmol / L, at least 36mmol / L, at least 37mm ol / L, at least 38mmol / L, at least 39mmol / L, at least 41mmol / L, at least 42mmol / L, at least 43mmol / L, at least 44mmol / L, at least 45mmol / L, at least 46mmol / L, at least 47mmol / L, at least 48mmol / L, at least 49mmol / L, at least 51mmol / L, at least 52mmol / L, at least 53mmol / L, at least 54mmol / L, at least 55mmol / L, at least 56mmol / L, at least 57mmol / L, at least 58mmol / L, at least 59mmol / L, at least 61mmol / L, at least 62mmol / L, at least 63mmol / L, at least 64mmol / L, at least 65mmol / L, at least 66mmol / L, at least 67mmol / L, at least 68mmol / L, at least 69mmol / L, at least 71mmol / L, at least 72mmol / L, at least 73mmol / L, at least 74mmol / L, at least 75mmol / L, at least 76mmol / L,In some embodiments, the pharmaceutical formulations of the present disclosure include a glutamic acid and histidine buffer at a concentration of at least 77 mmol / L, at least 78 mmol / L, at least 79 mmol / L, at least 81 mmol / L, at least 82 mmol / L, at least 83 mmol / L, at least 84 mmol / L, at least 85 mmol / L, at least 86 mmol / L, at least 87 mmol / L, at least 88 mmol / L, at least 89 mmol / L, at least 91 mmol / L, at least 92 mmol / L, at least 93 mmol / L, at least 94 mmol / L, at least 95 mmol / L, at least 96 mmol / L, at least 97 mmol / L, at least 98 mmol / L, or at least 99 mmol / L. In some embodiments, the pharmaceutical formulations of the present disclosure include a glutamic acid and histidine buffer at any concentration within the above ranges.

[0084] [000113] In some embodiments, the pharmaceutical formulation of the present disclosure comprises a glutamic acid & histidine buffer at up to 2 mmol / L, up to 3 mmol / L, up to 4 mmol / L, up to 5 mmol / L, up to 6 mmol / L, up to 7 mmol / L, up to 8 mmol / L, up to 9 mmol / L, up to 11 mmol / L, up to 12 mmol / L, up to 13 mmol / L, up to 14 mmol / L, up to 15 mmol / L, up to 16 mmol / L, up to 17 mmol / L, up to 18 mmol / L, up to 19 mmol / L, up to 22 mmol / L, up to 23 mmol / L, up to 24 mmol / L, up to 25 mmol / L, up to 26 mmol / L, up to 27 mmol / L, up to 28 mmol / L, up to 29 mmol / L, up to 30 mmol / L, up to 31 mmol / L, up to 32 mmol / L, up to 33 mmol / L, up to 34 mmol / L, up to 35 mmol / L, up to 36 mmol / L, up to 37 mmol / L, up to 38 mmol / L, up to 39 mmol / L, up to 40 mmol / L, up to 41 mmol / L, up to 42 mmol / L, up to 43 mmol / L, up to 44 mmol / L, up to 45 mmol / L, up to 46 mmol / L, up to 47 mmol / L, up to 48 mmol / L, up to 49 mmol / L, up to 50 mmol / L, up to 51 mmol / L, up to 52 mmol / L, up to 53 mmol / L, up to 54 mmol / L, up to 55 mmol / L, up to 56 mmol / L, up to 57 mmol / L, up to 58 mmol / L, up to mmol / L, max 22mmol / L, max 23mmol / L, max 24mmol / L, max 25mmol / L, max 26mmol / L, max 27mmol / L, max 28mmol / L, max 29mmol / L, max 31mmol / L, max 32mmol / L, max 33mmol / L, max 34mmol / L, max 35mmol / L, max 36mmol / L, max 37mmol / L, max 38mmol / L, max 39mmol / L, max 41mmol / L, max 42mmol / L, max 43mmol / L , max 44mmol / L, max 45mmol / L, max 46mmol / L, max 47mmol / L, max 48mmol / L, max 49mmol / L, max 51mmol / L, max 52mmol / L, max 53mmol / L, max 54mmol / L, max 55mmol / L, max 56mmol / L, max 57mmol / L, max 58mmol / L, max 59mmol / L, max 61mmol / L, max 62mmol / L, max 63mmol / L, max 64mmol / L, max 65mmol / L, max 66 mmol / L, max 67mmol / L, max 68mmol / L, max 69mmol / L, max 71mmol / L, max 72mmol / L, max 73mmol / L, max 74mmol / L, max 75mmol / L, max 76mmol / L, max 77mmol / L, max 78mmol / L, max 79mmol / L, max 81mmol / L, max 82mmol / L, max 83mmol / L, max 84mmol / L, max 85mmol / L, max 86mmol / L, max 87mmol / L, max 88mmol / LIn some embodiments, the pharmaceutical formulations of the present disclosure include a glutamic acid and histidine buffer, consisting of glutamic acid and histidine, at a concentration of at most 89 mmol / L, at most 91 mmol / L, at most 92 mmol / L, at most 93 mmol / L, at most 94 mmol / L, at most 95 mmol / L, at most 96 mmol / L, at most 97 mmol / L, at most 98 mmol / L, or at most 99 mmol / L.

[0085] [000114] Aspartic acid differs from glutamic acid by only one methylene group, and therefore, it can be expected that replacing glutamic acid in the above glutamic acid & histidine buffer with aspartic acid will achieve a similar technical effect (e.g., maintaining the correct pH of the finished pharmaceutical formulation).

[0086] [000115] stabilizers [000116] The pharmaceutical formulations of the present disclosure may include one or more stabilizers. As used herein, the term "stabilizer" refers to an agent that can promote maintenance of API structure and / or minimize electrostatic protein-protein interactions so that the finished pharmaceutical formulation is suitable for administration, and / or an agent that imparts a desired osmolality (e.g., isotonic, hypotonic, or hypertonic) to the pharmaceutical formulation. In other words, the stabilizers used in the pharmaceutical formulations of the present disclosure can also serve as isotonic agents that can impart an appropriate osmotic pressure to the drug to prevent net water flow across cell membranes that contact the drug. In some embodiments, the formulations of the present disclosure have an osmotic pressure substantially the same as human blood.

[0087] [000117] Exemplary stabilizers include, but are not limited to, polyols (e.g., sorbitol, mannitol), sugars (e.g., glucose, sucrose, trehalose, lactose), and / or salts (e.g., sodium chloride, sodium sulfate, ammonium acetate, potassium chloride, calcium phosphate).

[0088] [000118] In some embodiments, the stabilizer used in the pharmaceutical formulation of the present disclosure is selected from a sugar. In some embodiments, the stabilizer used in the pharmaceutical formulation of the present disclosure is selected from the group consisting of sucrose, trehalose, or a combination thereof. In some embodiments, the stabilizer used in the pharmaceutical formulation of the present disclosure is selected from a polyol. In some embodiments, the stabilizer used in the pharmaceutical formulation of the present disclosure is selected from the group consisting of sorbitol, mannitol, or a combination thereof.

[0089] [000119] In some embodiments, the type and concentration of stabilizer used in the pharmaceutical formulations of the present disclosure can be determined based on the desired osmolality of the final formulation. For example, about 5% sorbitol can achieve isotonicity, while about 9% sucrose would be required to achieve isotonicity. In certain embodiments, the pharmaceutical formulations of the present disclosure contain a stabilizer at a concentration of about 0.5% to 50% (w / v). In some embodiments, the stabilizer concentration is anywhere within the above range. For example, the pharmaceutical formulation of the present disclosure may contain a stabilizer in an amount of about 1% to about 40% (w / v), about 1.5% to about 39.5% (w / v), about 2% to about 39% (w / v), about 2.5% to about 38.5% (w / v), about 3% to about 38% (w / v), about 3% to about 36% (w / v), about 3% to about 34% (w / v), about 3% to about 32% (w / v), about 3% to about 30% (w / v), about 3% to about 28% (w / v), about 3% to about 26% (w / v), or about 3% to about 24% (w / v). % (w / v), about 3% to about 22% (w / v), about 3% to about 20% (w / v), about 3.2% to about 18% (w / v), about 3.4% to about 16% (w / v), about 2% to about 30% (w / v), about 3% to about 20% (w / v), about 3.2% to about 18% (w / v), about 3.4% to about 16% (w / v), about 3.6% to about 14% (w / v), about 4% to about 12% (w / v), about 6% to about 10% (w / v), or about 8% (w / v).

[0090] [000120] In some embodiments, the pharmaceutical formulations of the present disclosure contain a stabilizer in an amount of at least 0.5% (w / v), at least 1% (w / v), at least 1.5% (w / v), at least 2% (w / v), at least 2.5% (w / v), at least 3% (w / v), at least 3.5% (w / v), at least 4% (w / v), at least 4.5% (w / v), at least 5% (w / v), at least 5.5% (w / v), at least 6% (w / v), at least 6.5% (w / v), or at least at least 7% (w / v), at least 7.5% (w / v), at least 8% (w / v), at least 8.1% (w / v), at least 8.2% (w / v), at least 8.3% (w / v), at least 8.4% (w / v), at least 8.5% (w / v), at least 8.6% (w / v), at least 8.7% (w / v), at least 8.8% (w / v), at least 8.9% (w / v), at least 9% (w / v), at least 9.5% (w / v), at least 10% (w / v), at least 10.5% (w / v), at least 11% (w / v) ), at least 11.5% (w / v), at least 12% (w / v), at least 12.5% ​​(w / v), at least 13% (w / v), at least 13.5% (w / v), at least 14% (w / v), at least 14.5% (w / v), at least 15% (w / v), at least 15.5% (w / v), at least 16% (w / v), at least 16.5% (w / v), at least 17% (w / v), at least 17.5% (w / v), at least 18% (w / v), at least 18.5% (w / v), at least 19% (w / v), at least At least 19.5% (w / v), at least 20% (w / v), at least 20.5% (w / v), at least 21% (w / v), at least 21.5% (w / v), at least 22% (w / v), at least 22.5% (w / v), at least 23% (w / v), at least 23.5% (w / v), at least 24% (w / v), at least 24.5% (w / v), at least 25% (w / v), at least 25.5% (w / v), at least 26% (w / v), at least 26.5% (w / v), at least 27% (w / v), at least 27.5% (w / v), at least 28% (w / v), at least 28.5% (w / v), at least 29% (w / v), at least 29.5% (w / v), at least 30% (w / v), at least 30.5% (w / v), at least 31% (w / v), at least 31.5% (w / v), at least 32% (w / v), at least 32.5% (w / v), at least 33% (w / v), at least 33.5% (w / v), at least 34% (w / v), at least 34.5% (w / v), at least 35% (w / v), at least 35.5% (w / v), at least 36% (w / v), at least 36.5% (w / v), at least 37% (w / v), at least 37.5% (w / v), at least 38% (w / v), at least 38.5% (w / v), at least 39% (w / v), at least 39.5% (w / v), at least 40% (w / v), at least 40.5% (w / v), at least 41% (w / v), at least 41.5% (w / v), at least 42% (w / v), at least 42.5% (w / v), at least 43% (w / v), at least 43.5% (w / v), at least 44% (w / v), at least At a concentration of 44.5% (w / v), at least 45% (w / v), at least 45.5% (w / v), at least 46% (w / v), at least 46.5% (w / v), at least 47% (w / v), at least 47.5% (w / v), at least 48% (w / v), at least 48.5% (w / v), at least 49% (w / v), or at least 49.5% (w / v).

[0091] [000121] In some embodiments, the pharmaceutical formulations of the present disclosure may contain stabilizers at up to 1% (w / v), up to 1.5% (w / v), up to 2% (w / v), up to 2.5% (w / v), up to 3% (w / v), up to 3.5% (w / v), up to 4% (w / v), up to 4.5% (w / v), up to 5% (w / v), up to 5.5% (w / v), up to 6% (w / v), up to 6.5% (w / v), up to 7% (w / v), up to 7.5% (w / v), up to 8% (w / v), up to 8.1% (w / v), up to 8.2% (w / v), Max 8.3% (w / v), Max 8.4% (w / v), Max 8.5% (w / v), Max 8.6% (w / v), Max 8.7% (w / v), Max 8.8% (w / v), Max 8.9% (w / v), Max 9% (w / v), Max 9.5% (w / v), Max 10% (w / v), Max 10.5% (w / v), up to 11% (w / v), up to 11.5% (w / v), up to 12% (w / v), up to 12.5% ​​(w / v), up to 13% (w / v), up to 13.5% (w / v), up to 14% (w / v), up to 14.5% (w / v), up to 15% (w / v), up to 15.5% (w / v) , up to 16% (w / v), up to 16.5% (w / v), up to 17% (w / v), up to 17.5% (w / v), up to 18% (w / v), up to 18.5% (w / v), up to 19% (w / v), up to 19.5% (w / v), up to 20% (w / v), up to 20.5% (w / v), up to 2 1% (w / v), maximum 21.5% (w / v), maximum 22% (w / v), maximum 22.5% (w / v), maximum 23% (w / v), maximum 23.5% (w / v), maximum 24% (w / v), maximum 24.5% (w / v), maximum 25% (w / v), maximum 25.5% (w / v), maximum 26% (w / v), maximum 26.5% (w / v), maximum 27% (w / v), maximum 27.5% (w / v), maximum 28% (w / v), maximum 28.5% (w / v), maximum 29% (w / v), maximum 29.5% (w / v), maximum 30% (w / v), maximum 30.5% (w / v), maximum 31% (w / v), Up to 31.5% (w / v), Up to 32% (w / v), Up to 32.5% (w / v), Up to 33% (w / v), Up to 33.5% (w / v), Up to 34% (w / v), Up to 34.5% (w / v), Up to 35% (w / v), Up to 35.5% (w / v), Up to 36% (w / v), Up to 36.5% (w / v), maximum 37% (w / v), maximum 37.5% (w / v), maximum 38% (w / v), maximum 38.5% (w / v), maximum 39% (w / v), maximum 39.5% (w / v), maximum 40% (w / v), up to 40.5% (w / v), up to 41% (w / v), up to 41.5% (w / v), up to 42% (w / v), up to 42.5% (w / v), up to 43% (w / v), up to 43.5% (w / v), up to 44% (w / v), up to 44.5% (w / v), up to 45% (w / v), up to 45.5% (w / v), up to 46% (w / v), up to 46.5% (w / v), up to 47% (w / v), up to 47.5% (w / v), up to 48% (w / v), up to 48.5% (w / v), up to 49% (w / v), up to 49.5% (w / v), or up to 50% (w / v).

[0092] [000122] In some embodiments, the pharmaceutical formulations of the present disclosure include sucrose. In some embodiments, the pharmaceutical formulations of the present disclosure include sucrose at a concentration of about 4% to 12% (w / v), about 5% to 11% (w / v), about 6% to 10% (w / v), about 7% to 9% (w / v), or about 8% (w / v). In some embodiments, the pharmaceutical formulations of the present disclosure include sucrose at a concentration of about 8% (w / v).

[0093] [000123] In some embodiments, the pharmaceutical formulations of the present disclosure include sorbitol. In some embodiments, the pharmaceutical formulations of the present disclosure include sorbitol at a concentration of about 0.5% to 10% (w / v), about 1% to 9.5% (w / v), about 1.5% to 9% (w / v), about 2% to 8.5% (w / v), about 2.5% to 8% (w / v), about 3% to 7.5% (w / v), about 3.5% to 7% (w / v), about 4% to 6.5% (w / v), about 4.5% to 6% (w / v), about 5% to 5.5% (w / v), or about 4.5% (w / v). In some embodiments, the pharmaceutical formulations of the present disclosure include sorbitol at a concentration of about 4.5% (w / v).

[0094] [000124] In some embodiments, the pharmaceutical formulations of the present disclosure include trehalose. In some embodiments, the pharmaceutical formulations of the present disclosure include trehalose at a concentration of about 4% to 14% (w / v), about 5% to 13% (w / v), about 6% to 12% (w / v), about 7% to 11% (w / v), about 7.5% to 10.5% (w / v), about 8% to 10% (w / v), about 8.2% to 9.8% (w / v), about 8.4% to 9.6% (w / v), about 8.6% to 9.4% (w / v), about 8.8% to 9.2% (w / v), about 9.0% (w / v), or about 8.8% (w / v). In some embodiments, the pharmaceutical formulations of the present disclosure include trehalose at a concentration of about 8.8% (w / v).

[0095] [000125] In some embodiments, the pharmaceutical formulations of the present disclosure have an osmolality in the range of about 200-400 mOsmol kg, about 250-350 mOsmol kg, about 280-320 mOsmol kg, about 285 mOsmol kg, about 290 mOsmol kg, or about 300 mOsmol kg. In some embodiments, the pharmaceutical formulations of the present disclosure have an osmolality of 300±10 mOsmol kg.

[0096] [000126] surfactants [000127] The pharmaceutical formulations of the present disclosure may further comprise one or more surfactants to, for example, adjust osmolality, prevent, control, or minimize aggregation (e.g., interface-induced aggregation), particle formation, and / or surface adsorption (e.g., surface-induced degradation) during liquid formulation processing, lyophilization of lyophilized formulations, reconstitution, and / or transport of the pharmaceutical formulation. Specifically, a surfactant surface layer can prevent protein molecules from adsorbing at sufficient concentrations (e.g., about the surfactant micelle concentration) at interfaces, thus minimizing surface-induced degradation of the API. As used herein, the term "surfactant" refers to a substance (e.g., an organic substance with an amphiphilic structure that is both hydrophilic and hydrophobic) that functions to reduce the surface tension of a liquid in which it is dissolved. Surfactants can be classified as ionic (e.g., anionic, cationic) and nonionic surfactants depending on the charge of the surface-active moiety. Surfactants are well known in the art and descriptions thereof can be found, for example, in Randolph T W and Jones L S, Surfactant-protein interactions. Pharm Biotechnol. 13:159-75 (2002).

[0097] [000128] Exemplary ionic surfactants include, but are not limited to, anionic, cationic, and zwitterionic surfactants. Exemplary anionic surfactants include, but are not limited to, sulfonic acid surfactants or carboxylic acid surfactants, such as fatty acid salts, soap, ammonium lauryl sulfate, sodium dodecyl sulfate (SDS), and other alkyl sulfates. Exemplary cationic surfactants include, but are not limited to, quaternary ammonium surfactants, such as acetylpyridinium chloride, benzalkonium chloride, acetyltrimethylammonium bromide (CTAB), and polyethoxylated tallowamine (POEA). Exemplary zwitterionic surfactants include, but are not limited to, dodecyldimethylamine oxide, cocamidopropyl betaine, dodecyl betaine, and cocoamphoglycinate.

[0098] [000129] Exemplary nonionic surfactants include, but are not limited to, alkyl poly(ethylene oxide), alkyl polyglucosides (e.g., octyl glucoside and decyl maltoside), fatty alcohols (e.g., acetyl alcohol and oleyl alcohol), cocamide DEA, cocamide MEA, cocamide TEA, poloxamers (e.g., poloxamer 188, poloxamer 407), Triton, polyethylene glycol, polypropylene glycol, and copolymers of ethylene glycol and propylene glycol (e.g., Pluronics, PF68, etc.), and polysorbates (e.g., polysorbate 20, polysorbate 28, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 81, and polysorbate 85).

[0099] [000130] In some embodiments, the pharmaceutical formulation of the present disclosure contains a surfactant at a concentration of about 0.001 to 0.1% w / v. In some embodiments, the surfactant concentration is any value within the above range. For example, the pharmaceutical formulation of the present disclosure contains a surfactant at a concentration of about 0.002% to about 0.08% (w / v), about 0.004% to about 0.06% (w / v), about 0.006% to about 0.05% (w / v), about 0.008% to about 0.05% (w / v), about 0.01% to about 0.05% (w / v), about 0.02% to about 0.04% (w / v), about 0.02% to about 0.03% (w / v), or about 0.02% (w / v).

[0100] [000131] In some embodiments, the pharmaceutical formulations of the present disclosure contain a surfactant in an amount of at least 0.002% (w / v), at least 0.003% (w / v), at least 0.004% (w / v), at least 0.005% (w / v), at least 0.006% (w / v), at least 0.007% (w / v), at least 0.008% (w / v), at least 0.009% (w / v), at least 0.01% (w / v), at least 0.012% (w / v), at least 0.014% (w / v), or at least 0.016% (w / v), depending on the particular surfactant and the desired stability of the pharmaceutical formulation. % (w / v), at least 0.016% (w / v), at least 0.018% (w / v), at least 0.02% (w / v), at least 0.022% (w / v), at least 0.024% (w / v), at least 0.026% (w / v), at least 0.028% (w / v), at least 0.03% (w / v), at least 0.032% (w / v), at least 0.034% (w / v), at least 0.036% (w / v), at least 0.038% (w / v), at least 0.04% (w / v), at least 0.042% (w / v) , at least 0.044% (w / v), at least 0.046% (w / v), at least 0.048% (w / v), at least 0.05% (w / v), at least 0.052% (w / v), at least 0.054% (w / v), at least 0.056% (w / v), at least 0.058% (w / v), at least 0.06% (w / v), at least 0.062% (w / v), at least 0.064% (w / v), at least 0.066% (w / v), at least 0.068% (w / v), at least 0.07% (w / v), at least Also included are concentrations of 0.072% (w / v), at least 0.074% (w / v), at least 0.076% (w / v), at least 0.078% (w / v), at least 0.08% (w / v), at least 0.082% (w / v), at least 0.084% (w / v), at least 0.086% (w / v), at least 0.088% (w / v), at least 0.09% (w / v), at least 0.092% (w / v), at least 0.094% (w / v), at least 0.096% (w / v), or at least 0.098% (w / v).

[0101] [000132] In some embodiments, the pharmaceutical formulations of the present disclosure may contain surfactants at up to 0.002% (w / v), up to 0.003% (w / v), up to 0.004% (w / v), up to 0.005% (w / v), up to 0.006% (w / v), up to 0.007% (w / v), up to 0.008% (w / v), up to 0.009% (w / v), up to 0.01% (w / v), up to 0.012% (w / v), up to 0.016% (w / v), up to 0.018% (w / v), up to 0.019% (w / v), up to 0.020% (w / v), up to 0.021% (w / v), up to 0.022% (w / v), up to 0.024% (w / v), up to 0.025% (w / v), up to 0.026% (w / v), up to 0.027% (w / v), up to 0.028% (w / v), up to 0.029% (w / v), up to 0.030% (w / v), up to 0.031% (w / v), up to 0.032% (w / v), up to 0.033% (w / v), up to 0.034% (w / v), up to 0.035% (w / v), up to 0.036% (w / v), up to 0.037% (w / v), up to 0.038% (w / v), up to 0.039% (w / v), up to 0.040% (w / v), up to 0.041% (w / v), up to 0.042% (w .014%(w / v), max. 0.016%(w / v), max. 0.018%(w / v), max. 0.02%(w / v), max. 0.022%(w / v), max. 0.024%(w / v), max. 0.026%(w / v), max. 0.028% (w / v), maximum 0.03% (w / v), maximum 0.032% (w / v), maximum 0.034% (w / v), maximum 0.036% (w / v), maximum 0.038% (w / v), maximum 0.04% (w / v), maximum 0.042% (w / v), Max 0.044%(w / v), Max 0.046%(w / v), Max 0.048%(w / v), Max 0.05%(w / v), Max 0.052%(w / v), Max 0.054%(w / v), Max 0.056%(w / v), Max 0.0 58% (w / v), maximum 0.06% (w / v), maximum 0.062% (w / v), maximum 0.064% (w / v), maximum 0.066% (w / v), maximum 0.068% (w / v), maximum 0.07% (w / v), maximum 0.072% (w / v), up to 0.074% (w / v), up to 0.076% (w / v), up to 0.078% (w / v), up to 0.08% (w / v), up to 0.082% (w / v), up to 0.084% (w / v), up to 0.086% (w / v), up to 0.088% (w / v), up to 0.09% (w / v), up to 0.092% (w / v), up to 0.094% (w / v), up to 0.096% (w / v), up to 0.098% (w / v), or up to 0.1% (w / v).

[0102] [000133] In some embodiments, the pharmaceutical formulations of the present disclosure include polysorbate 20. In some embodiments, the pharmaceutical formulations of the present disclosure include polysorbate 80. In some embodiments, the pharmaceutical formulation of the present disclosure comprises polysorbate 80 at a concentration of about 0.01-0.05% (w / v), about 0.012-0.048% (w / v), about 0.014-0.046% (w / v), about 0.016-0.044% (w / v), about 0.018-0.042% (w / v), about 0.02-0.04% (w / v), about 0.022-0.038% (w / v), about 0.024-0.036% (w / v), about 0.026-0.034% (w / v), about 0.028-0.032% (w / v), or about 0.03% (w / v). In some embodiments, the pharmaceutical formulation of the present disclosure comprises polysorbate 80 at a concentration of about 0.02% (w / v).

[0103] [000134] Other materials [000135] The pharmaceutical formulations of the present disclosure may further include one or more other excipients, such as those described in Remington's Pharmaceutical Sciences, 16th Edition, Osol, A. Ed. (1980), such as a diluent, provided that the one or more other excipients do not adversely affect the desired characteristics of the pharmaceutical formulations of the present disclosure.

[0104] [000136] The term "diluent" refers to a pharmaceutically acceptable agent that can be used to dilute the pharmaceutical formulations of the present disclosure. Typical diluents include water, saline, injectable antibacterial agents, pH buffers, sterile saline, Ringer's solution, or glucose solution. In certain embodiments, the pharmaceutical formulations of the present disclosure further comprise a diluent comprising 0.9% saline or 5% glucose.

[0105] [000137] API [000138] One of ordinary skill in the art will appreciate that the pharmaceutical formulations described herein are equally applicable to many types of APIs, including the exemplified APIs (e.g., antibodies or antigen-binding fragments thereof), as well as other APIs known in the art.

[0106] [000139] In some embodiments, the API of the pharmaceutical formulation of the present disclosure is a monoclonal antibody or antigen-binding fragment thereof. [000140] As used herein, the term "monoclonal antibody" refers to a population of antibodies that are homogeneous or substantially homogeneous and contain a single antibody. Monoclonal antibodies can be obtained from a single hybridoma cell clone (Milstein, C (1999). "The hybridoma revolution: an offshoot of basic research". BioEssays. 21(11):966-73). An intact monoclonal antibody contains two heavy chains and two light chains. Each heavy chain contains a heavy chain variable region (V H ) and the first, second, and third constant regions (C H1 , C H2 , C H3 Each light chain consists of a light chain variable region (V L ) and the light chain constant region (C L ) in the heavy and light chains. H and V L Each of the monoclonal antibodies contains three complementarity-determining regions (CDRs). The three CDRs are separated by adjacent regions known as framework regions (FRs), which are more highly conserved than the CDRs and form a scaffold supporting the hypervariable loops. The six CDRs of one heavy chain and one light chain together constitute the antigen-binding portion of an antibody and determine its specificity. The monoclonal antibodies described herein also include fragments or derivatives of the intact monoclonal antibody that retain antigen-binding function. The fragment or derivative has the same antigen-binding specificity as the intact monoclonal antibody, but the affinity of the fragment or derivative for binding to its specific antigen may be the same as or different from the affinity of the intact monoclonal antibody.

[0107] [000141] In some embodiments, the monoclonal antibodies described herein comprise antigen-binding fragments. An antigen-binding fragment is one or more antibody fragments that retain the ability to specifically bind to an antigen. Examples of antigen-binding fragments include, but are not limited to, (i) Fab fragments, which are V L , V H , C L , and C H1 (ii) Fab' fragment, which is a Fab fragment containing part of the hinge region; (iii) F(ab')2 fragment, which is a bivalent fragment containing two Fab fragments linked by a disulfide bond at the hinge region; (iv) V H and C H1 (v) a single arm V of an antibody; L and V H (vi) dAb fragments containing a single variable domain (Ward et al., Nature 341:544-546 (1989); WO 90 / 05144); (vii) isolated CDRs; (viii) single-chain Fv fragments, which contain V fragments linked directly or via a peptide chain. L and V H It refers to a monovalent fragment formed from a domain (Huston JS et al., Proc Natl Acad Sci USA, 85:5879 (1988)).

[0108] [000142] In some embodiments, the monoclonal antibodies described herein include chimeric monoclonal antibodies in which a portion of the heavy and / or light chains are identical to or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, and the remaining chains are identical to or homologous to corresponding sequences in antibodies and fragments thereof derived from other species or belonging to other antibody classes or subclasses, so long as they exhibit the desired functional activity.

[0109] [000143] In some embodiments, the monoclonal antibodies described herein comprise human-mouse chimeric monoclonal antibodies having murine heavy and light chain variable regions and human heavy and light chain constant regions.

[0110] [000144] In some embodiments, the monoclonal antibodies described herein include humanized monoclonal antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (e.g., Fv, Fab, Fab', F(ab')2, or other antigen-binding sequences of antibodies) that contain minimal sequence derived from non-human immunoglobulin. In some examples, humanized antibodies are characterized by the amino acid sequences of the human CDRs being replaced by those of the non-human V. H and V L The humanized antibody may also be a CDR-grafted antibody, in which amino acid residues of a receptor are introduced into the amino acid sequence of a non-human antibody to replace the amino acid sequence of the corresponding non-human CDR. In another example, most of the amino acid sequence of the humanized antibody may be derived from a human immunoglobulin (receptor antibody) in which the amino acid residues of the receptor's CDR are replaced by amino acid residues of the CDR of a non-human (e.g., mouse, rat, rabbit) antibody having the desired specificity, affinity, and capacity. Generally, a humanized antibody essentially comprises at least one, and generally two, variable domains, with all or substantially all of the CDR regions corresponding to the sequence of a non-human immunoglobulin and all or substantially all of the framework (FR) regions being human immunoglobulin sequences. In some examples, framework region residues of the human immunoglobulin variable regions are replaced by corresponding non-human residues. Furthermore, humanized antibodies may contain residues that are found neither in the receptor antibody nor in the imported CDR or framework region sequences.

[0111] [000145] In certain embodiments, the API of the pharmaceutical preparation of the present disclosure is a monoclonal anti-OX40 antibody or its antigen-binding fragment.The monoclonal anti-OX40 antibody described herein is a monoclonal antibody that specifically binds to OX40 receptor protein.In certain embodiments, the monoclonal anti-OX40 antibody or its antigen-binding fragment of the pharmaceutical preparation of the present disclosure is an antagonist antibody that has blocking activity against OX40-mediated signal transduction.

[0112] [000146] The OX40 receptor protein, also known as CD134 or tumor necrosis factor receptor superfamily, member 4 (TNFRSF4), is a member of the TNFR superfamily of receptors. OX40 is a secondary costimulatory immune checkpoint molecule that is not constitutively expressed on resting naive T cells but can be expressed after T cell activation. Binding of OX40 ligand to the OX40 receptor on T cells is thought to prevent T cell death and subsequently increase cytokine production. The monoclonal anti-OX40 antibody or antigen-binding fragment thereof of the pharmaceutical formulation of the present disclosure can block the binding of OX40 ligand to OX40, preventing OX40 trimerization and thus suppressing T cell activation and the associated inflammatory response induced by OX40 activation.

[0113] [000147] In some embodiments, the monoclonal anti-OX40 antibodies described herein comprise a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain CDR1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 1, a HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2, and a heavy chain variable region V comprising the amino acid sequence set forth in SEQ ID NO: 3. H and the light chain comprises a light variable region V comprising a light chain CDR1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 4, an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 5, and an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 6. L Includes.

[0114] [000148] In some embodiments, the monoclonal anti-OX40 antibodies described herein comprise a heavy chain variable region V comprising an amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9, and SEQ ID NO:10. H In some embodiments, the monoclonal anti-OX40 antibodies described herein comprise a light chain variable region V comprising an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:11, and SEQ ID NO:12. L In some embodiments, the monoclonal anti-OX40 antibodies described herein comprise a heavy chain variable region V comprising the amino acid sequence of SEQ ID NO:7. H In some embodiments, the monoclonal anti-OX40 antibodies described herein comprise a light chain variable region V comprising the amino acid sequence of SEQ ID NO:8. L In some embodiments, the monoclonal anti-OX40 antibodies described herein comprise a heavy chain variable region V comprising the amino acid sequence of SEQ ID NO:7. H and a light chain variable region V comprising the amino acid sequence of SEQ ID NO: 8 L In some embodiments, the monoclonal anti-OX40 antibodies described herein comprise a heavy chain variable region V comprising the amino acid sequence of SEQ ID NO:9. H and a light chain variable region V comprising the amino acid sequence of SEQ ID NO: 11 L In some embodiments, the monoclonal anti-OX40 antibodies described herein comprise a heavy chain variable region V comprising the amino acid sequence of SEQ ID NO: 10. H and a light chain variable region V comprising the amino acid sequence of SEQ ID NO: 8 L In some embodiments, the monoclonal anti-OX40 antibodies described herein comprise a heavy chain variable region V comprising the amino acid sequence of SEQ ID NO:7. H and a light chain variable region V comprising the amino acid sequence of SEQ ID NO: 11 L In some embodiments, the monoclonal anti-OX40 antibodies described herein comprise a heavy chain variable region V comprising the amino acid sequence of SEQ ID NO: 10. H and a light chain variable region V comprising the amino acid sequence of SEQ ID NO: 12 L Includes.

[0115] [000149] In some embodiments, the monoclonal anti-OX40 antibodies described herein further comprise an immunoglobulin constant region. In some embodiments, the immunoglobulin constant region comprises a heavy chain constant region and / or a light chain constant region. The heavy chain constant region comprises a C H1 , C H1 ~C H2 , or C H1 ~C H3 The light chain constant region is C L In some embodiments, the monoclonal anti-OX40 antibodies described herein further comprise an Fc region variant, wherein the variant is human IgG1 N297A. The term "IgG1 N297A" refers to an IgG1 Fc region variant in which asparagine at position 297 is substituted with alanine relative to the parent polypeptide (i.e., the wild-type Fc region of IgG1), where this number corresponds to the EU index.

[0116] [000150] In some embodiments, the monoclonal anti-OX40 antibodies described herein are monoclonal antibodies comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 13 and a light chain comprising the amino acid sequence of SEQ ID NO: 14. The nucleic acid sequences encoding the heavy and light chains of the monoclonal anti-OX40 antibodies described herein comprise SEQ ID NO: 15 and SEQ ID NO: 16, respectively.

[0117] [000151] The above APIs may contain additional post-translational modifications such as glycosylation, oxidation, and deamidation. For example, the monoclonal anti-OX40 antibodies described herein have their V H and / or V L In particular, V including SEQ ID NO: 7 may contain glycosylation sites, oxidation sites and / or deamidation sites. H and V comprising SEQ ID NO: 8 LIn the monoclonal anti-OX40 antibody having the following structure, potential oxidation sites are shown in bold in the amino acid sequences shown in SEQ ID NO:7 and SEQ ID NO:8 in Table 1 below. Potential deamination sites are shown in italics and bold in the amino acid sequences shown in SEQ ID NO:7 and SEQ ID NO:8 in Table 1 below. Potential isomerization sites are shown in underlined and bold in the amino acid sequences shown in SEQ ID NO:7 and SEQ ID NO:8 in Table 1 below.

[0118] [000152] Exemplary amino acid sequences in some embodiments are listed in Table 1 below:

[0119] [Table 1-1]

[0120] [Table 1-2]

[0121] [Table 1-3]

[0122] [Table 1-4]

[0123] [000153] The pharmaceutical formulations of the present disclosure can contain the monoclonal anti-OX40 antibody or antigen-binding fragment thereof at a concentration ranging from 0.5 to 200 mg / ml. In some embodiments, the concentration of the monoclonal anti-OX40 antibody or antigen-binding fragment thereof is any concentration value within the above range. For example, depending on the need, the concentration of the monoclonal anti-OX40 antibody in the pharmaceutical formulation is about 1 to 180 mg / ml, about 10 to 160 mg / ml, about 15 to 140 mg / ml, about 20 to 120 mg / ml, about 25 to 100 mg / ml, about 30 to 80 mg / ml, about 40 to 60 mg / ml, or about 50 mg / ml.

[0124] [000154] In certain embodiments, the pharmaceutical formulations of the present disclosure can include the monoclonal anti-OX40 antibody or antigen-binding fragment thereof at a concentration of at least 0.5 mg / ml, at least 1 mg / ml, at least 2 mg / ml, at least 3 mg / ml, at least 4 mg / ml, at least 5 mg / ml, at least 6 mg / ml, at least 7 mg / ml, at least 8 mg / ml, at least 9 mg / ml, at least 10 mg / ml, at least 20 mg / ml, at least 30 mg / ml, at least 40 mg / ml, at least 50 mg / ml, at least 60 mg / ml, at least 70 mg / ml, at least 80 mg / ml, at least 90 mg / ml, at least 100 mg / ml, at least 120 mg / ml, at least 140 mg / ml, at least 160 mg / ml, or at least 180 mg / ml.

[0125] [000155] In certain embodiments, pharmaceutical formulations of the present disclosure can include the monoclonal anti-OX40 antibody or antigen-binding fragment thereof at a concentration of up to 200 mg / ml, up to 180 mg / ml, up to 160 mg / ml, up to 140 mg / ml, up to 120 mg / ml, up to 100 mg / ml, up to 90 mg / ml, up to 80 mg / ml, up to 70 mg / ml, up to 60 mg / ml, up to 50 mg / ml, up to 40 mg / ml, up to 30 mg / ml, up to 20 mg, up to 10 mg / ml, up to 9 mg / ml, up to 8 mg / ml, up to 7 mg / ml, up to 6 mg / ml, up to 5 mg / ml, up to 4 mg / ml, up to 3 mg / ml, up to 2 mg / ml, or up to 1 mg / ml.

[0126] [000156] In certain embodiments, the pharmaceutical formulation of the present disclosure can include one or more of the monoclonal anti-OX40 antibodies or antigen-binding fragments thereof. The concentration of the monoclonal anti-OX40 antibodies or antigen-binding fragments thereof can vary depending on various factors, such as, for example, API activity, mode of administration, indication to be treated, treatment regimen, and whether the pharmaceutical formulation is intended for long-term storage in lyophilized or liquid form. Those skilled in the art can easily determine the approximate concentration of the API without undue experimentation.

[0127] [000157] In some embodiments, the pharmaceutical formulations of the present disclosure may contain a monoclonal anti-OX40 antibody at a concentration of about 40-60 mg / ml. In some embodiments, the pharmaceutical formulations of the present disclosure may contain a monoclonal anti-OX40 antibody at a concentration of about 35-55 mg / ml, about 40-50 mg / ml, or about 50 mg / ml. In some embodiments, the pharmaceutical formulations of the present disclosure may contain a monoclonal anti-OX40 antibody at a concentration of about 50 mg / ml.

[0128] [000158] Methods of Formulation Preparation [000159] The present disclosure also provides methods for preparing the pharmaceutical formulations provided herein. The methods can include combining a buffer solution having a pH of about 5.0 to about 8.0 (e.g., about 5.0 to about 5.5), a stabilizer, a surfactant, and a therapeutically effective amount of one or more APIs. One or more of the excipients in the pharmaceutical formulations described herein can be combined with a therapeutically effective amount of one or more APIs to create a wide range of pharmaceutical formulations. Buffers, stabilizers, surfactants, and APIs are described above in the "Formulations" section.

[0129] [000160] Generally, pharmaceutical formulations should be sterile, which can be achieved by using sterile reagents in a sterile manufacturing environment or by preparation followed by sterilization. For example, a sterile pharmaceutical formulation can be prepared by incorporating one or more APIs in the required amount into a buffer along with other excipients described herein (e.g., stabilizers and surfactants) before applying a sterilization method such as microfiltration.

[0130] [000161] In certain embodiments, the methods of preparing pharmaceutical formulations provided herein include a formulation step comprising: 1) Prepare a concentrated API (e.g., a monoclonal anti-OX40 antibody or antigen-binding fragment thereof) (from ultrafiltration / diafiltration, UF / DF) at a concentration of 63±6 mg / ml (e.g., 47 mg / ml, 48 mg / ml, 49 mg / ml, 50 mg / ml, 51 mg / ml, 52 mg / ml, 53 mg / ml, 54 mg / ml, 55 mg / ml, 56 mg / ml, 57 mg / ml, 58 mg / ml, 59 mg / ml, 60 mg / ml, 61 mg / ml, 62 mg / ml, or 63 mg / ml) in 20 mM glutamate / histidine buffer at pH 5.0; 2) adding sucrose from a stock solution of 40% (w / v) to the concentrated API to a final concentration of 8% (w / v); 3) Add polysorbate 80 from a stock solution of 10% (w / w) polysorbate 80 to the UF / DF pool to a final concentration of 0.02% (w / v); 4) Filter the formulated bulk through a 0.2 μm filter and then package it into PC bottles. A 40% (w / w) sucrose stock solution and a 10% (w / w) polysorbate 80 stock solution can be prepared in 20 mM glutamic acid / histidine at pH 5.0.

[0131] [000162] In certain embodiments, the method for preparing the pharmaceutical formulations provided herein can further include cell culture and purification steps prior to the formulation step. The cell culture step can proceed using vial thawing and seed culture growth in shake flasks, cell growth in an RM bioreactor, cell growth in an XDR 200 L bioreactor, production culture in a SUB 500 L bioreactor, and depth filtration harvest. The purification step can be performed using affinity chromatography (AC), low-pH viral inactivation and neutralization (VIN), intermediate depth filtration (Int. DF), anion exchange (AEX) chromatography, cation exchange (CEX) chromatography, virus filtration (VF), and ultrafiltration / diafiltration (UF / DF).

[0132] [000163] Once the pharmaceutical formulation has been prepared as described above, the stability of one or more APIs contained within the pharmaceutical formulation can be assessed using methods known in the art, such as those used in the Examples, including, but not limited to, size exclusion chromatography, particle counting, anion / cation exchange chromatography, functional assays such as binding activity, etc.

[0133] [000164] kit [000165] Also provided herein are kits containing one or more containers, each containing one or more excipients and API(s) described above. In certain embodiments, the kits contain, in one or more containers, a buffer such as glutamic acid and histidine buffer or aspartic acid and histidine buffer, a stabilizer such as sucrose, sorbitol, or trehalose, a surfactant such as PS80, and a monoclonal anti-OX40 antibody or antigen-binding fragment thereof, and instructions for use thereof.

[0134] [000166] In certain embodiments, the kits provided herein include one or more single- or multi-chamber syringes, such as liquid syringes and lyosyringes, for administering the pharmaceutical formulations of the present disclosure. The kits provided herein can include pharmaceutical formulations for human use.

[0135] [000167] use [000168] In another aspect, the present disclosure further provides a method for treating an OX40-related disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the present disclosure. As used herein, the term "OX40-related disease" refers to a disease requiring treatment with an OX40 agonist or antagonist, such as cancer, or an inflammatory disease and / or autoimmune disease. As used herein, the term "inflammatory disease and / or autoimmune disease" refers to any inflammatory or immune-related condition, such as pathological inflammation and autoimmune disease. As used herein, the term "autoimmune disease" refers to a disease or condition caused by or targeting a subject's own tissues or organs. For example, the generation of B cells that produce antibodies that recognize normal body tissues and antigens can cause autoimmune disease; the secretion of autoantibodies specific to epitopes derived from autoantigens can also cause autoimmune disease.

[0136] [000169] In certain embodiments, the cancer is selected from the group consisting of breast cancer, melanoma, small cell lung cancer, renal cancer, gastric cancer, liver cancer, ovarian cancer, lympho-leukocyte melanoma, prostate cancer, urothelial cancer, head and neck cancer, non-small cell lung cancer, mesothelioma, skin cancer, lymphoma, leukemia, and sarcoma.

[0137] [000170] In certain embodiments, the inflammatory and / or autoimmune disease is selected from the group consisting of idiopathic dermatitis, autoimmune uveitis, scleroderma, multiple sclerosis, lupus (e.g., systemic lupus erythematosus), rheumatoid arthritis, asthma (e.g., allergic asthma), chronic obstructive pulmonary disease (COPD), ulcerative colitis, and graft-versus-host disease (GVHD).

[0138] [000171] The pharmaceutical formulations of the present disclosure can be administered by one or more routes of administration using one or more of a variety of methods known in the art. As one of ordinary skill in the art will recognize, the route and / or mode of administration will vary depending on the desired results. Preferred routes of administration include intravenous, intramuscular, intradermal, intraperitoneal, subcutaneous, spinal, or other parenteral routes of administration, for example, by injection or infusion. A more preferred route of administration is intravenous or subcutaneous. As used herein, the phrase "parenteral administration" refers to modes of administration other than enteral and topical administration, usually by injection, and includes, but is not limited to, intravenous, intramuscular, intraarterial, intrathecal, intraarticular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injection and infusion. Alternatively, the pharmaceutical formulations of the present disclosure may be administered by non-parenteral routes, such as topical, epithelial or mucosal routes of administration, for example, intranasally, orally, vaginally, rectally, sublingually or topically.

[0139] [000172] In some embodiments, the pharmaceutical formulations of the present disclosure are suitable for subcutaneous administration or via intravenous infusion. In some embodiments, the pharmaceutical formulations of the present disclosure that are suitable for subcutaneous administration comprise a monoclonal anti-OX40 antibody or fragment thereof at a concentration of about 50 mg / mL.

[0140] [000173] The pharmaceutical formulations of the present disclosure can be administered in a single dose or multiple doses. As used herein, the terms "dose" and "dosage" are interchangeable and refer to the amount of drug substance administered per subject's body weight or the total dose administered to a subject regardless of body weight.

[0141] [000174] In some embodiments, a therapeutically effective amount of the pharmaceutical formulation of the present disclosure is administered to a patient in need thereof. As used herein, the term "therapeutically effective amount" refers to the minimum concentration required to achieve a detectable improvement or prevention of a particular disease or condition. The ability of a pharmaceutical formulation to improve or prevent a particular disease or condition can be assessed, for example, in an animal model system or an in vitro system, which predicts efficacy for the target disease or condition in humans. The dosage of an API in the pharmaceutical formulation of the present disclosure can be determined based on various factors, such as the size and location of the area to be treated, the subject's weight, the severity of the subject's symptoms, the nature of the selected API (e.g., whole antibody or fragment), the mode of administration, and any additional agents administered before, during, or after administration of the API in the pharmaceutical formulation of the present disclosure.

[0142] [000175] In yet another aspect, the disclosure provides the use of the pharmaceutical formulation in the manufacture of a medicament for the treatment of an OX40-associated disease. [000176] Other embodiments of the formulation [000177] Embodiment 1. An antibody or antigen-binding fragment. a buffer selected from a glutamic acid and histidine buffer or an aspartic acid and histidine buffer; a stabilizing agent selected from sucrose, sorbitol, or trehalose at a concentration of about 0.5% to about 50% (w / v); A surfactant at a concentration of about 0.001% to about 0.1% (w / v) that is polysorbate 80 and having a pH of about 5.0 to about 8.0.

[0143] [000178] Embodiment 2 The pharmaceutical formulation of embodiment 1, wherein the buffering agent is present in a concentration of about 1-100 mmol / L, about 10-90 mmol / L, about 10-80 mmol / L, about 10-70 mmol / L, about 10-60 mmol / L, about 10-50 mmol / L, about 10-40 mmol / L, about 10-30 mmol / L, or about 20 mmol / L.

[0144] [000179] Embodiment 3 The pharmaceutical formulation of embodiment 1 or 2, wherein the buffering agent is present in a concentration of about 10-30 mmol / L. [000180] Embodiment 4 The pharmaceutical formulation of any one of the preceding embodiments, wherein the buffering agent is present in a concentration of about 20 mmol / L.

[0145] [000181] Embodiment 4 The pharmaceutical formulation of any one of the preceding embodiments, wherein the pharmaceutical formulation has a pH of about 5.0 to about 6.0. [000182] Embodiment 5. The pharmaceutical formulation of any one of the preceding embodiments, wherein the pharmaceutical formulation has a pH of about 5.0 to about 5.5.

[0146] [000183] Embodiment 6 The pharmaceutical formulation of any one of the preceding embodiments, wherein the pharmaceutical formulation has a pH of about 5.0. [000184] Embodiment 7 The pharmaceutical formulation of any one of the preceding embodiments, wherein the stabilizer is present in a concentration of about 0.5% to about 50% (w / v), about 1% to about 40% (w / v), about 2% to about 30% (w / v), about 3% to about 20% (w / v), about 3.2% to about 18% (w / v), about 3.4% to about 16% (w / v), about 3.6% to about 14% (w / v), about 4% to about 12% (w / v), about 6% to about 10% (w / v), or about 8% (w / v).

[0147] [000185] Embodiment 8 The pharmaceutical formulation of any one of the preceding embodiments, wherein the stabilizer is sucrose at a concentration of about 4% to about 12% (w / v). [000186] Embodiment 9 The pharmaceutical formulation of any one of the preceding embodiments, wherein the stabilizer is sucrose at a concentration of about 8% (w / v).

[0148] [000187] Embodiment 10 The pharmaceutical formulation of any one of the preceding embodiments, wherein the stabilizer is sorbitol at a concentration of about 0.5% to about 10% (w / v). [000188] Embodiment 11 The pharmaceutical formulation of any one of Embodiments 1-7, wherein the stabilizer is sorbitol at a concentration of about 4.5% (w / v).

[0149] [000189] Embodiment 12 The pharmaceutical formulation of any one of Embodiments 1-7, wherein the stabilizer is trehalose at a concentration of about 4% to 14% (w / v). [000190] Embodiment 13 The pharmaceutical formulation of any one of Embodiments 1-7, wherein the stabilizer is trehalose at a concentration of about 8.8% (w / v).

[0150] [000191] Embodiment 14 The pharmaceutical formulation of any one of the preceding embodiments, wherein polysorbate 80 is present in a concentration of about 0.002% to about 0.08% (w / v), about 0.004% to about 0.06% (w / v), about 0.006% to about 0.05% (w / v), about 0.008% to about 0.05% (w / v), about 0.01% to about 0.05% (w / v), or about 0.02% (w / v).

[0151] [000192] Embodiment 15 The pharmaceutical formulation of any one of the preceding embodiments, wherein polysorbate 80 is present in a concentration of about 0.01% to about 0.04% (w / v), about 0.01% to about 0.03% (w / v), or about 0.02% (w / v).

[0152] [000193] Embodiment 16 The pharmaceutical formulation of any one of the preceding embodiments, wherein the polysorbate 80 is present in a concentration of about 0.02% (w / v). [000194] Embodiment 17 The pharmaceutical formulation of any one of the preceding embodiments, wherein the antibody or antigen-binding fragment is present at a concentration of about 0.5-200 mg / ml, about 1-180 mg / ml, about 10-160 mg / ml, about 15-140 mg / ml, about 20-120 mg / ml, about 25-100 mg / ml, about 30-80 mg / ml, about 40-60 mg / ml, or about 50 mg / ml.

[0153] [000195] Embodiment 18 The pharmaceutical formulation of any one of the preceding embodiments, wherein the antibody or antigen-binding fragment is present at a concentration of about 45-55 mg / ml, or about 50 mg / ml.

[0154] [000196] Embodiment 19 The pharmaceutical formulation of any one of the preceding embodiments, wherein the antibody or antigen-binding fragment is present in a concentration of about 50 mg / ml. [000197] Embodiment 20 The pharmaceutical formulation of any one of the preceding embodiments, wherein the antibody or antigen-binding fragment is a monoclonal anti-OX40 antibody or antigen-binding fragment thereof.

[0155] [000198] Embodiment 21. The pharmaceutical formulation of embodiment 20, wherein the monoclonal anti-OX40 antibody comprises a heavy chain and a light chain, and the heavy chain comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1; HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 2; HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 3 A heavy chain variable region V comprising H Including, The light chain is LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 4; LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 5; LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6 a light chain variable region V comprising L Includes.

[0156] [000199] Embodiment 22 The pharmaceutical formulation of embodiment 21, wherein the monoclonal anti-OX40 antibody further comprises an Fc region variant. [000200] Embodiment 23 The pharmaceutical formulation of embodiment 22, wherein the Fc region variant is human IgG1 N297A.

[0157] [000201] Embodiment 24. A pharmaceutical formulation of any one of the preceding embodiments, comprising a heavy chain variable region V H comprises an amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9, and SEQ ID NO:10.

[0158] [000202] Embodiment 25. The pharmaceutical formulation of any one of embodiments 20 to 24, wherein the light chain variable region V Lcomprises an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:11, and SEQ ID NO:12.

[0159] [000203] Embodiment 26. The pharmaceutical formulation of any one of embodiments 20 to 25, comprising a heavy chain variable region V H and light chain variable region V L The pairs are selected from the group consisting of SEQ ID NO:7 and SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:11, SEQ ID NO:10 and SEQ ID NO:8, SEQ ID NO:7 and SEQ ID NO:11, SEQ ID NO:10 and SEQ ID NO:12.

[0160] [000204] Embodiment 27 The pharmaceutical formulation of any one of Embodiments 1-26, wherein the pharmaceutical formulation is suitable for subcutaneous or intravenous administration. [000205] Embodiment 28. Use of the pharmaceutical formulation of any one of embodiments 1-27 in the manufacture of a medicament for the treatment or prevention of an OX40-associated disease.

[0161] [000206] Embodiment 29 The use of embodiment 28, wherein the OX40-associated disease is an inflammatory and / or autoimmune disease (such as graft-versus-host disease). [000207] Embodiment 30. A method of treating an OX-related disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical formulation of any one of embodiments 1-27.

[0162] [000208] Embodiment 31. The method of embodiment 30, wherein the administration is by subcutaneous injection or intravenous injection. [Example]

[0163] [000209] The present disclosure can be better understood with reference to the following examples. However, the following examples are intended to illustrate the present disclosure and should not be construed as limiting the scope of the present disclosure. Various changes and modifications may be made in light of the teachings herein, and therefore, such changes and modifications are within the scope of the present disclosure.

[0164] [000210] This study reported solubility profiling studies, pH / buffer screening, as well as excipient screening and surfactant strength screening for pharmaceutical formulations of the present disclosure.

[0165] [000211] Solubility profiling studies investigated acetate buffer, citrate / arginine buffer, and arginine buffer with PEG concentration studies and Tag. Formulation stability was investigated at 40±2°C and 75±5% relative humidity in nine different pH / buffer conditions for up to four weeks of incubation.

[0166] [000212] For excipient screening and surfactant strength screening, seven different formulations were examined under several conditions: incubation at 40°C for 2 or 4 weeks, freeze-thawing from -70°C to room temperature for 3 or 5 cycles, and agitation at 300 rpm for 1 or 3 days.

[0167] Example 1: Analysis Method [000213] Appearance [000214] The exterior walls of the glass vials were wiped, and then the necks of the glass vials were held near the edge of the gobo of a YB-2 lightbox at a distance of 25 cm. The appearance of the samples, including color, transparency, and visible particles, was examined against a black and white background at an illumination intensity of 2000 to 3750 Lux.

[0168] [000215] PEG concentration study [000216] The final PEG concentration was set to 2.5%-15%. 50 μL of the PEG stock solution was added to 50 μL of well-mixed sample solution containing protein. The protein concentration was then detected by Nanodrop. A curve of PEG concentration vs. protein concentration was then obtained.

[0169] [000217] Protein concentration [000218] After mixing the samples to homogeneity, protein concentrations were determined by UV280 readings using a NanoDrop 2000 spectrophotometer. The extinction coefficient was 1.62 AU. * mL * mg -1* cm -1 All measurements were repeated twice with a loading volume of 2.5 μL each time and averaged.

[0170] [000219] pH [000220] The pH meter was calibrated prior to use using three different standard buffers (pH 4.01, 7.00, and 9.21). The calibration slope was 95.0% to 105.0% and the zero drift was -60.0 mv to +60.0 mv. The pH was then measured for each sample with a loading volume of 50 μL.

[0171] [000221] Osmotic pressure [000222] The osmolality of 20 μL of undiluted sample was measured twice using a Model 2020 Osmometer and averaged. Before and after the measurement, the osmometer was calibrated with a 290 mOsm reference solution.

[0172] [000223] DSC [000224] DSC is a thermoanalytical technique that measures the difference in the amount of heat required to raise the temperature of a sample and a reference as a function of temperature. Samples were diluted to 1 mg / mL in their reference buffers. 400 μL of each reference buffer was added to odd-numbered wells of a 96-well plate, and 400 μL of sample was added to even-numbered wells of the same plate. Experimental parameters were set to scan temperatures from 10 to 95°C at a rate of 90°C / h. Analysis of the thermograms was performed with MicroCal PEAQ DSC automated data analysis software.

[0173] [000225] Caliper-SDS [000226] Caliper-SDS is a purity method used to determine the truncation or fragmentation of biomolecules during production and storage processes. Caliper-SDS uses a microchip to separate proteins based on their electrophoretic mobility. Smaller proteins migrate faster and larger proteins migrate slower in the capillary.

[0174] [000227] In this study, samples were first diluted to 1.0 mg / mL with ultrapure water and then mixed with a denaturing solution composed of sample buffer, SDS, and N-ethylmaleimide (for non-reducing methods) or dithiothreitol (for reducing methods). The mixture was incubated at 70°C for 10 minutes and then transferred to a 96-well plate. After the plate was placed on the instrument's plate holder, the samples were aliquoted, stained, separated, and detected on a microchip. Data were acquired using the LabChip GX Reviewer.

[0175] [000228] The percentage of the main peak was reported as the purity of the sample in the non-reduced Caliper-SDS (Caliper-SDS-NR). In the reduced method (Caliper-SDS-R), the percentage of the total LC+HC (purity) was reported.

[0176] [000229] SEC-HPLC [000230] SEC-HPLC was used to provide information about protein stability under certain conditions, e.g., as measured by protein aggregation during storage. Data can be presented as a percentage of the main peak (monomer), with a higher main peak percentage indicating less protein aggregation (e.g., dimers and other high molecular weight aggregates).

[0177] [000231] SEC was performed on an Agilent HPLC system using an SEC column (300 x 7.8 mm, 5 μm). The sampler temperature was set to 5 ± 3°C, and the column oven temperature was set at 25 ± 3°C. The mobile phase was 50 mM PB, 300 mM NaCl, pH 6.8 ± 0.1, and the flow rate was set at 1.0 mL / min. 100 μg of each sample was injected. The detection wavelength was set at 280 nm, and the run time was 20 min.

[0178] [000232] iCIEF [000233] Imaging capillary isoelectric focusing (iCIEF) is a purity method used to monitor charge variant species by determining the isoelectric point (pI) and distribution of each variant.

[0179] [000234] Charge variants of proteins are separated based on their unique pI, which is an intrinsic property of a particular protein and is the pH at which the protein molecule carries no net charge. Under an external electric field, charge variants migrate along a continuous pH gradient formed by ampholytes and stop at a position where the pH is equal to their pI.

[0180] [000235] In this study, protein samples were first diluted to 1.0 mg / mL with ultrapure water. 20 μL of the diluted sample was then mixed with 80 μL of a master mix consisting of pI markers 4.65 / 9.22, carrier amphoteric (3–10), methylcellulose, and urea before being loaded into a capillary for electrophoresis using a capillary isoelectric focusing system.

[0181] [000236] The percentages of the main peak, acidic peak, and basic peak were reported in the final results, along with the pI of the main peak. The acidic peak represents acidic species, defined as antibody variants that elute earlier than the main peak during cation exchange chromatography (CEX) or later than the main peak during anion exchange chromatography (AEX) analysis. Acidic species can be formed through modifications including sialic acid, deamidation, non-classical disulfide bonds, trisulfide bonds, high mannose, glycation, maleuric acid modifications, cysteinylation, reduced disulfide bonds, non-reduced species, and / or fragments. The basic peak represents basic species, defined as material that elutes later than the main peak during CEX and earlier than the main peak during AEX analysis. Basic species can be formed through modifications including isomerization of C-terminal Lys, N-terminal Glu, and Asp, succinimide, Met oxidation, amidation, incomplete disulfide bonds, incomplete leader sequence removal, Ser to Arg mutation, glycosylation, fragments, and / or aggregates. The "main peak" refers to the main species and represents the target antibody molecule eluting as the primary peak on the chromatogram. The main species does not necessarily correspond to unmodified or undegraded antibody. In fact, the main peak typically consists of antibody species with three types of typical post-translational modifications: (1) cyclization of N-terminal glutamine (Gln) to pyroGlu; (2) removal of C-terminal lysine (Lys) from the heavy chain; and (3) glycosylation of the conserved asparagine (Asn) residue in the CH2 domain with neutral oligosaccharides.

[0182] [000237] MFI [000238] Submicroscopic particles were monitored by the MFI System 5200. A 1.5 mL volume of each sample was transferred to an MFI 96-well plate in a biosafety hood for analysis. Results were analyzed by the vendor's software. The amount of submicroscopic particles with equivalent circular diameters > 2 μm, > 5 μm, > 10 μm, and > 25 μm was reported.

[0183] [000239] Tagg (agglomeration temperature) [000240] Tagg is a thermoanalytical parameter used to predict the thermodynamic stability of proteins, which can be characterized by dynamic light scattering (DLS).

[0184] [000241] Measurements were performed on a Wyatt DynaPro plate reader II. Before the experiment, both sides of the 384-well plate were purged with clean nitrogen to keep them clean. Then, 20 μL of sample was added to the corresponding position and centrifuged at 4000 rpm for 5 minutes. Finally, 15 μL of paraffin oil was dropped onto the sample for liquid sealing. During detection, the sample was heated from 25°C to 75°C, and data analysis was completed using the software provided by the instrument manufacturer.

[0185] [000242] kD [000243] kD is a thermoanalytical parameter used to predict the thermodynamic stability of proteins, which can be characterized by DLS. Measurements were performed on a Wyatt DynaPro plate reader II. Before the experiment, both sides of a 384-well plate were purged with clean nitrogen to keep them clean. Then, 20 μL of sample was added to the corresponding position and centrifuged at 4000 rpm for 5 minutes. Finally, 15 μL of paraffin oil was dropped onto the sample for liquid sealing. During detection, the sample was incubated at 20 ° C, 25 ° C, 30 ° C, 35 ° C, and 40 ° C. Data analysis was completed using software provided by the instrument manufacturer.

[0186] Example 2: Soluble Profiling [000244] the purpose [000245] This study aimed to understand the relationship between solubility, pH and pH / ionic strength for buffer screening.

[0187] [000246] material [000247] The anti-OX40 antibody drug substance (DS) has a heavy chain of SEQ ID NO:13 and a light chain of SEQ ID NO:14.

[0188] [000248] Experimental Method [000249] Anti-OX40 antibody drug substance (DS) was exchanged into acetate buffer (a buffer system consisting essentially of acetic acid and sodium acetate), citrate / arginine buffer (a buffer system consisting essentially of citric acid and arginine), and arginine buffer (a buffer system consisting essentially of arginine and arginine-HCl) by ultracentrifugal filtration. A protein concentration of 2 mg / mL was obtained by filtering through a 0.22 μm PVDF syringe filter. The PEG concentration was set to 2.5% to 15%, and then 50 μL of the sample was thoroughly mixed with 50 μL of PEG. The protein concentration was then determined by UV280. 8% sucrose was added to each sample for the Tagg assay. The study design is shown in Table 2.

[0189] [000250]

[0190] [Table 2]

[0191] [000251] result [000252]PEG [000253] As shown in Table 3 and Figure 1, no obvious change in protein concentration was observed in acetate buffer pH 4.5. The protein concentration in arginine buffer decreased when the PEG concentration was 10%.

[0192] [000254]

[0193] [Table 3]

[0194] [000255]Tagg [000256] As shown in Table 4, the Tag temperatures of the anti-OX40 antibody were 59.1°C, 60.3°C, 58.7°C, and 59.0°C at pH 4.5, 5.0, 8.0, and 8.5, respectively.

[0195] [000257]

[0196] [Table 4]

[0197] [000258] summary [000259] Based on the results of the solubility profiling study, the solubility of the anti-OX40 antibody is best in acetate buffer at pH 4.5 than in other buffers, and the anti-OX40 antibody has a higher aggregation temperature at lower ionic strength.

[0198] Example 3: pH / Buffer Screening Studies [000260] the purpose [000261] This study aimed at pH / buffer screening for optimal protein storage.

[0199] [000262] material [000263] The anti-OX40 antibody drug substance (DS) has a heavy chain of SEQ ID NO: 13 and a light chain of SEQ ID NO: 14. The acetate buffer is a buffer system consisting essentially of acetic acid and sodium acetate, the glutamine / histidine buffer is a buffer system consisting essentially of glutamic acid and histidine, and the arginine buffer is a buffer system consisting essentially of arginine and arginine-HCl, optionally with an acid (e.g., HCl) or base (e.g., NaOH) to adjust the final pH.

[0200] [000264] Experimental Method [000265] Anti-OX40 antibody DS was exchanged into acetate, glutamine / histidine, and arginine buffer by ultrafiltration and diafiltration (UF / DF). 50 mg / mL protein was filtered through a 0.22 μm PVDF syringe filter and subsequently aliquoted into 2R vials (50 mg / vial). The vials were stoppered and capped and subjected to stability studies at 40°C as shown in Table 5.

[0201] [000266]

[0202] [Table 5]

[0203] [000267] result [000268]DSC [000269] The DSC results are shown in Table 6 and Figure 2. The Tmonset of anti-OX40 antibody DS in arginine buffer pH 8.0 (57.0°C) was higher than that in other buffers. The Tmonset of anti-OX40 antibody DS in acetate buffer was close to that in glutamine / histidine buffer. These results indicated that the thermal stability of anti-OX40 antibody DS was worse at low pH. Tmonset represents the temperature at which the protein begins to unravel, indicating the temperature at which the first domain of the protein begins to unravel. Tml represents the thermal transition midpoint, indicating the temperature at which the first protein domain is half-unraveled.

[0204] [000270]

[0205] [Table 6]

[0206] [000271] Appearance, pH and protein concentration [000272] Appearance, pH, and protein concentration are shown in Table 7. Visible particles were observed in all buffers after 4 weeks. Only in the arginine buffer were particles observed after 1 week. No significant changes in color, pH, or protein concentration were observed.

[0207] [000273]

[0208] [Table 7-1]

[0209] [Table 7-2]

[0210] [000274]SEC-HPLC [000275] The SEC-HPLC results are summarized in Table 8, and the compositions of the main peak, aggregates, and fragments are presented in Figures 3, 4, and 5. The main peak at pH 4.5 showed a maximum decrease of 11.4% and 11.1% in acetate and glutamine / histidine buffers, respectively. The HMW peak increased by 7.0% and 6.1%, while the LMW peak increased by 4.3% and 5.0%. The main peak in glutamine / histidine buffer showed a negligible decrease of 4.7% at pH 5.5.

[0211] [000276]iCIEF [000277] The iCIEF results are summarized in Table 8, and the compositions of the main, acidic, and basic peaks are shown in Figures 6, 7, and 8. The main peak in arginine buffer showed a maximum decrease of 56.4% at pH 8.5. The main peak decreased by 29.4% and 29.2% in acetate and glutamine / histidine buffers at pH 4.5, respectively.

[0212] [000278] Caliper-SDS (reduced & non-reduced) (Caliper-SDS-R & Caliper-SDS-NR) [000279] Caliper-SDS (reduced & non-reduced) results are summarized in Table 8, and the purity change of anti-OX40 antibody DS is presented in Figure 9 and Figure 10. The purity of non-reduced protein at pH 8.5 in arginine buffer decreased by 12.8%. The purity of non-reduced protein at pH 5.0 and 5.5 in acetate and glutamine / histidine buffer decreased by about 3%, and the purity at other pH conditions decreased by about 7%.

[0213] [000280] The purity of the reduced protein decreased by 2.5% and 1.4% at pH 5.0 and 5.5 in acetate buffer, values ​​similar to those in glutamine / histidine buffer. At pH 4.5 in acetate buffer and pH 8.5 in arginine buffer, the reduced protein results showed a maximum decrease of 10.9% and 10.3%, respectively.

[0214] [000281]

[0215] [Table 8-1]

[0216] [Table 8-2]

[0217] [000282] Efficacy [000283] Potency was measured by a binding assay performed with the following steps: coating plate, coating antigen (OX40-Fc), plate blocking, incubation, stopping, and reading. Binding potency, expressed as %, is the percentage of the level of anti-OX40 antibody DS binding to antigen (OX40-Fc) after storage compared to the level of anti-OX40 antibody DS binding to antigen at the start. Potency results are shown in Table 9. No significant changes in potency were observed.

[0218] [000284]

[0219] [Table 9]

[0220] [000285]Conclusion [000286] Based on the results of the pH / buffer screening study, the stability of anti-OX40 antibody DS was better in acetate buffer and glutamine / histidine buffer at pH 5.0 and 5.5 than in other buffers. SEC-HPLC and Caliper-SDS results showed that aggregation and fragmentation were observed at pH 4.5 and 8.5. The results of HMW in glutamine / histidine buffer were better than in acetate buffer.

[0221] [000287] iCIEF results showed that the chemical transformation of anti-OX40 antibody DS at pH 5.0 and 5.5 was slower than at other pH conditions. [000288] In summary, 20 mM glutamine / histidine buffer pH 5.0 is suggested for anti-OX40 antibody DS, with pH 5.5 added as backup.

[0222] Example 4: Excipient Screening and Surfactant Strength Screening [000289] the purpose [000290] This study aimed at excipient screening and surfactant strength screening for optimal protein storage.

[0223] [000291] material [000292] The anti-OX40 antibody drug substance (DS) has a heavy chain of SEQ ID NO:13 and a light chain of SEQ ID NO:14.

[0224] [000293] Experimental Methods [000294] Anti-OX40 antibody DS was dialyzed against 20 mM glutamine / histidine buffer. 40% sucrose, 44% trehalose 2H2O, 22.5% sorbitol, 10% PS80, and 10% PS20 stock solutions were formulated (see Table 10). Each formulation was filtered through a 0.22 μm PVDF membrane filter and then aseptically filled into 2R vials (2 mL / vial). All vials were stoppered and capped immediately after filling. Vials filled with each formulation were subjected to stress conditions: a 40°C incubator, freeze-thawing (-70°C to RT), and agitation (300 rpm, 25°C). Samples were tested at each sampling time point listed in Table 11.

[0225] [000295]

[0226] [Table 10]

[0227] [000296]

[0228] [Table 11]

[0229] [000297] result [000298]DSC [000299] The DSC results were shown in Table 12 and Figure 11. The Tmonset of the anti-OX40 antibody DS in formulation F7 (53.0°C) was higher than that in the other formulations, which was about 51°C.

[0230] [000300]

[0231] [Table 12]

[0232] [000301] Appearance, pH, protein concentration and osmolality [000302] The results of appearance, pH, and protein concentration are shown in Table 13. A small number of visible particles were observed in formulation 4 after 4 weeks of incubation at 40°C without PS80, freeze-thawing, and agitation, and in formulation F6 after 4 weeks of incubation at 40°C. There were no significant changes in pH and protein concentration for all formulations under investigation. These data suggest that surfactants are essential for the stability of pharmaceutical compositions of the present disclosure, for example, during freeze-thawing, 4 weeks of storage at 40°C (PS80 is preferred over PS20), and / or 3 days of agitation.

[0233] [000303]

[0234] [Table 13-1]

[0235] [Table 13-2]

[0236] [Table 13-3]

[0237] [000304]

[0238] [Table 14]

[0239] [000305]SEC-HPLC [000306] As shown in Table 15, the compositions of the main peak, aggregates, and fragments presented in Figures 12, 13, and 14, no significant changes were observed in SEC-HPLC after 5 freeze-thaw cycles and 3 days of agitation at 25°C. After 4 weeks of storage at 40°C, the main peak showed a maximum decrease of 14.0% in Formulation F5 and a negligible decrease of 5.1% in Formulation F4.

[0240] [000307]iCIEF [000308] The results for the main peak, acidic peak, and basic peak compositions are shown in Table 15, Figure 15, Figure 16, and Figure 17. No significant changes were observed in iCIEF after five freeze-thaw cycles and 3 days of agitation at 25°C. After 4 weeks of storage at 40°C, the main peak results showed a maximum decrease of 29.5% for Formulation F5 and a negligible decrease of 23.7% for Formulation F4.

[0241] [000309] Caliper-SDS(N&NR) [000310] The changes in purity of anti-OX40 antibody DS are presented in Table 15, Figure 18, and Figure 19. No significant changes were observed in Caliper-SDS (R&NR) after five freeze-thaw cycles and 3 days of agitation at 25°C. After 4 weeks of storage at 40°C, the non-reduced results for formulations F3 and F7 showed a decrease of 5.5% and 5.3%, respectively. The reduced results for formulation F7 showed a negligible decrease of 1.3%, and no significant differences were observed for the other formulations.

[0242] [000311]

[0243] [Table 15-1]

[0244] [Table 15-2]

[0245] [Table 15-3]

[0246] [000312] Particles that cannot be seen without a microscope [000313] As shown in Table 16, formulation F6 had an increase in submicroscopic particles after 4 weeks of incubation at 40° C. Formulation F4 without PS80 had an increase in submicroscopic particles after 5 freeze-thaw cycles and 3 days of agitation at 25° C.

[0247] [000314]

[0248] [Table 16]

[0249] [000315] Efficacy [000316] As shown in Table 17, no significant change in potency was observed after 4 weeks of incubation at 40°C.

[0250] [000317]

[0251] [Table 17]

[0252] [000318] kD and Tag [000319] the purpose [000320] Based on the results of the excipient screening and surfactant strength screening studies, kD and Tagg investigated protein diffusion and aggregation using different surfactant strengths.

[0253] [000321] Experimental Method [000322] A spare sample of Formulation F4 (20 mM glutamine / histidine pH 5.0, 8% (w / v) sucrose) was filtered through a 0.22 μm PVDF membrane filter and diluted to different protein concentrations with formulation buffer. 10% PS80 stock solution was incorporated into the formulation. Protein concentrations and surfactant strengths are shown in Table 18. Only 2 mg / mL, 6 mg / mL, and 10 mg / mL were tested by Tagg. The temperatures in kD were 20°C, 25°C, 30°C, 35°C, and 40°C.

[0254] [000323]

[0255] [Table 18]

[0256] [000324] kD results [000325] As shown in Table 19, the kD results in the formulation with 0.04% PS80 were worse than the other formulations.

[0257] [000326]

[0258] [Table 19]

[0259] [000327] Tagg results [000328] As shown in Table 20, no significant differences were observed among all formulations. [000329]

[0260] [Table 20]

[0261] [000330]Conclusion [000331] The stability of anti-OX40 antibody DS was investigated in different formulation conditions and different surfactant strengths containing sucrose, trehalose, sorbitol, PS80, and PS20, respectively, after 4 weeks of incubation at 40°C, 5 cycles of freeze-thawing, and agitation at 300 rpm.

[0262] [000332] The results showed no significant difference between sucrose, trehalose, and sorbitol in stabilizing proteins. Visible particles were observed in the formulation with PS20 after 4 weeks of incubation at 40°C. The main peak of SEC-HPLC showed a maximum decrease of 14.0% in the formulation with 0.08% PS80, which means that higher surfactant strength was not good for protein conformation.

[0263] [000333] The kD results showed that the diffusion of anti-OX40 antibody DS in the formulation with 0.04% PS80 was weaker than in the formulations with 0.01% PS80 and 0.02% PS80 or no PS80, but was still acceptable.

[0264] [000334] Therefore, two formulations were recommended as formulations for anti-OX40 antibody DS in formulation validation studies: 20 mM glutamine / histidine buffer pH 5.0, 8% (w / v) sucrose, 0.02% (w / v) PS80 and 20 mM glutamine / histidine buffer pH 5.0, 8% (w / v) sucrose, 0.04% (w / v) PS80.

[0265] [000335] The optimized pharmaceutical formulations are summarized in Table 21 below. [000336]

[0266] [Table 21]

[0267] Example 5: Long-term stability studies for pharmaceutical formulations [000337] Two batches of the pharmaceutical formulation of the present disclosure (Non-GMP Batch No. 1 and GMP Batch No. 2, see Table 22) were prepared using anti-OX40 antibody DS, glutamine / histidine buffer (prepared from 9.39 mmol / L glutamic acid and 10.61 mmol / L histidine), sucrose, and polysorbate 80, where the concentration of anti-OX40 antibody DS was 50 mg / ml, the concentration of glutamine / histidine buffer was 20 mmol / L, the concentration of sucrose was 8% (w / v), and the concentration of polysorbate 80 was 0.02% (w / v), and the pH of the formulation was about 5.0. A long-term stability study was performed on the two batches of pharmaceutical formulation by storing them under the storage conditions shown in Table 23, and samples were taken periodically to measure the stability of the pharmaceutical formulation. Quality attributes monitored included color, clarity, pH, polysorbate 80 content, visible particles, submicroscopic particulate matter, CEX-HPLC, SEC-UPLC, CE-SDS (reduced and non-reduced), protein concentration, binding capacity, sterility, and container integrity testing (CCIT). CCIT was performed annually and at the expiration of long-term storage conditions.

[0268] [Table 22]

[0269] [Table 23]

[0270] [000338] The 3-month stability data for Non-GMP Batch No. 1 and GMP Batch No. 2 are shown in Table 24 and Table 25. No trends or significant differences were observed between the two batches at long-term storage conditions.

[0271] [Table 24]

[0272] [Table 25]

[0273] Example 6: Animal studies on toxicity and toxicokinetics [000339] the purpose [000340] The objective of this study is to determine the potential toxicity of the pharmaceutical formulations provided herein when administered by intravenous (IV) infusion to cynomolgus monkeys over a 29-day period on days 1, 8, 15, 22, and 29. The reversibility, residual, or delayed onset of toxic effects following a 28-day recovery period will also be assessed. Additionally, the toxicokinetics (TK), immunogenicity, and safety pharmacology of the pharmaceutical formulations provided herein will be determined.

[0274] [000341] Experimental design [000342] Forty cynomolgus monkeys (20 / sex) will be randomly assigned to four groups of five / sex / group to assess toxicity on days 1, 8, 15, 22, and 29 after weekly intravenous (IV) infusion of the pharmaceutical formulations shown in Table 26. The control group will receive vehicle. Animals will be randomly assigned to groups by Provantis based on body weight. The study design is shown in Table 27.

[0275] [000343]

[0276] [Table 26]

[0277] [000344] The final two monkeys / gender / group are assigned for recovery. [000345] All available dosing animals in groups 1-4 will be necropsied on day 30. All available recovery animals in groups 1-4 will be necropsied on day 58.

[0278] [Table 27]

[0279] [000346] Evaluation criteria [000347] Evaluation criteria included survival (morbidity / mortality), clinical findings, body weight, food consumption, clinical pathology (hematology, blood chemistry, coagulation, urinalysis), body temperature, organ weights, gross (necropsy) evaluation, histopathological evaluation, immunogenicity / immunotoxicity evaluation, and toxicokinetics.

Claims

1. A pharmaceutical formulation comprising a monoclonal anti-OX40 antibody or antigen-binding fragment thereof, a buffer, a stabilizer, and a surfactant.

2. The monoclonal anti-OX40 antibody comprises a heavy chain and a light chain, the heavy chain being HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 1; HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2; HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3 A heavy chain variable region V comprising Ｈ Including, Light chains LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 4; LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 5; LCDR3 comprising the amino acid sequence shown in SEQ ID NO:6 a light chain variable region V comprising Ｌ Including, the heavy chain further comprises an Fc region variant, wherein the Fc region variant is human IgG1 N297A; The pharmaceutical formulation of claim 1.

3. Heavy chain variable region V Ｈ comprises an amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9, and SEQ ID NO:10; and / or the light chain variable region V L comprises an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:11, and SEQ ID NO:12; The pharmaceutical formulation of claim 2.

4. the concentration of the monoclonal anti-OX40 antibody in the pharmaceutical formulation is about 0.5-200 mg / ml, preferably about 40-60 mg / ml; and / or the pharmaceutical formulation has a pH of about 5.0 to 8.0; and / or the buffer is selected from the group consisting of acetate buffer, histidine buffer, citrate buffer, glutamate buffer, arginine buffer, citrate & arginine buffer, glutamate & histidine buffer, aspartate & histidine buffer, and the concentration of the buffer in the pharmaceutical formulation is about 1-100 mmol / L; and / or the stabilizer is selected from the group consisting of sucrose, sorbitol, trehalose, xylitol and mannose, and the concentration of the stabilizer in the pharmaceutical formulation is about 0.5% to 50% w / v; and / or the surfactant is selected from the group consisting of polysorbate 80 and polysorbate 20, and the concentration of the surfactant in the pharmaceutical formulation is about 0.001-0.1% w / v; The pharmaceutical formulation according to any one of claims 1 to 3.

5. 4. The pharmaceutical formulation of claim 1, wherein the concentration of the monoclonal anti-OX40 antibody in the pharmaceutical formulation is about 40-60 mg / ml, the concentration of the buffer in the pharmaceutical formulation is about 10-30 mmol / L, the concentration of the stabilizer in the pharmaceutical formulation is about 4-12% w / v, the concentration of the surfactant in the pharmaceutical formulation is about 0.01-0.05% w / v, and / or the pharmaceutical formulation has a pH of about 5.0-6.

0.

6. 4. The pharmaceutical formulation of claim 1, wherein the concentration of the monoclonal anti-OX40 antibody in the pharmaceutical formulation is about 50 mg / ml, the concentration of the buffer in the pharmaceutical formulation is about 20 mmol / L, the concentration of the stabilizer in the pharmaceutical formulation is about 4.5-8.8% w / v, the concentration of the surfactant in the pharmaceutical formulation is about 0.02-0.04% w / v, and / or the pharmaceutical formulation has a pH of about 5.0-5.

5.

7. 4. The pharmaceutical formulation of claim 1, wherein the concentration of the stabilizer in the pharmaceutical formulation is about 8% w / v, the concentration of the surfactant in the pharmaceutical formulation is about 0.02% w / v, and / or the pharmaceutical formulation has a pH of about 5.

0.

8. the buffer is a glutamic acid and histidine buffer, an aspartic acid and histidine buffer, or a combination thereof; and / or the stabilizing agent is sucrose, sorbitol, trehalose, or a combination thereof; and / or The surfactant is polysorbate 80. The pharmaceutical formulation according to any one of claims 1 to 3.

9. a monoclonal anti-OX40 antibody or antigen-binding fragment thereof at a concentration of about 40-60 mg / ml; glutamic acid & histidine buffer or aspartic acid & histidine buffer at a concentration of about 10 to 30 mmol / L; sucrose at a concentration of about 4-12% w / v, and Polysorbate 80 at a concentration of about 0.01-0.05% w / v Including, the pharmaceutical formulation has a pH of about 5.0 to 5.5; The pharmaceutical formulation according to any one of claims 1 to 3.

10. a monoclonal anti-OX40 antibody or antigen-binding fragment thereof at a concentration of about 50 mg / ml; glutamic acid & histidine buffer or aspartic acid & histidine buffer at a concentration of about 20 mmol / L; sucrose at a concentration of about 8% w / v, and Polysorbate 80 at a concentration of about 0.02% w / v Including, The pharmaceutical formulation has a pH of about 5.

0. The pharmaceutical formulation according to any one of claims 1 to 3.

11. The pharmaceutical formulation according to any one of claims 1 to 3, wherein the pharmaceutical formulation is suitable for subcutaneous administration or for intravenous administration.

12. Use of the pharmaceutical formulation according to any one of claims 1 to 3 in the manufacture of a medicament for the treatment or prevention of an OX40-related disease.

13. The use according to claim 12, wherein the OX40-associated disease is an inflammatory and / or autoimmune disease such as graft-versus-host disease.

14. The use of claim 12, wherein the drug is administered by subcutaneous or intravenous injection.

15. 4. A method for preparing the pharmaceutical formulation of any one of claims 1 to 3, comprising combining a buffer, a stabilizer, a surfactant, and a pharmaceutically effective amount of a monoclonal anti-OX40 antibody or antigen-binding fragment thereof.

16. A kit comprising the pharmaceutical formulation of any one of claims 1 to 3 in one or more containers, optionally further comprising instructions for using the kit.

Images